Pathogenesis of Neurological Manifestations in LONG COVID and Spike Protein Associated Pathologies 

The persistence or emergence of long-term symptoms following resolution of primary SARS-CoV-2 infection is referred to as long COVID or post-acute sequelae of COVID-19 (PASC). PASC predominantly affects the cardiovascular, neurological, respiratory, gastrointestinal, reproductive, and immune systems.  Neurological manifestations are among the primary occurrences of long COVID. (105) (109)  Symptoms include fatigue memory disorders, cognitive impairment, sleep disorder, concentration impairment headache,dizziness, depression anxiety, neuropathic pain, dysautonomia, tremor and more. (109)

Long COVID affects about 6 percent of people with COVID, with more than 200 symptoms recorded.   It is unlikely that a single pathway accounts for this complex disease. 

Post-vaccination syndrome has recently gained attention in the scientific community, yet its formal recognition remains elusive. This condition, characterized by long-lasting symptoms similar to long COVID, affects a percentage of vaccine recipients.  (Halma M 2025)

The number of individuals affected by the COVID vaccine remains unclear  ADD data here 

Long COVID/ Long VAX  neurological manifestations result from a cascade of pathophysiological mechanisms that persist beyond the acute stage of SARS-CoV-2 infection. The most common neurological symptoms are brain fog, headache, loss of memory, dizziness, sleep disturbances, and confusion [1]. Autonomic dysfunction is also a very common problem.   This analysis presents evidence-based pathogenic mechanisms specifically in patients experiencing these prolonged neurological symptoms. Each mechanism may build upon the previous, creating self-perpetuating cycles that maintain chronic neurological dysfunction months to years post-infection.  These symptoms can be profoundly disabling .
It has become clear that there are various Long COVID phenotypes

The  VITAE survey, along with patient-facing data from the Yale LISTEN study, has consistently pointed to the same conclusion: that PCVS (post covid vaccine syndrome) is not exceedingly rare, it is not psychological, and mainstream institutions are not adequately addressing it.

PACVS refers to the chronic and often disabling constellation of symptoms that follow one or more COVID vaccine doses. Symptoms include:

• Exhaustion
• Debility
• Brain fog and cognitive impairment
• Paresthesia (tingling/prickling)
• Orthostatic intolerance
• Muscle and joint pain
• Sleep disturbances
• Dizziness and neuropsychiatric effects
• Neurodegenerative disease 

Several studies point out that neurological symptoms or CNS damage cannot be solely attributed to viral infection (Solomon, 2021) and there is limited or no evidence of active viral replication in the brains of individuals with Post-Acute Sequelae of SARS-CoV-2 (PASC) (van den Bosch et al., 2022) A recent study indicates that the infection is not required for cognitive impairment in long COVID (Fernandez-Castaneda et al., 2022). (Poso A) 

Autopsy studies of COVID-19 patients show infiltration of macrophages, CD8 + T lymphocytes in perivascular regions, and widespread microglial activation throughout the brain (Matschke et al., 2020). Interestingly, single-cell analysis of brain tissue demonstrated CD8 + T lymphocyte infiltration and microglial activation, but without evidence of viral RNA detection in brain parenchyma cells (Fullard et al., 2021).

It is of note that  SARS-CoV-2 is the only coronavirus with a prion-like domain found in the RBD of the S1 region of SP (Tetz and Tetz, 2022) 

The pathophysiological summaries presented in this document correlate not only with Long COVID but also with Post COVID Vaccine Syndromes.  

Central to understanding this condition is the role of the spike protein (SP), which can persist in the body and the brain long after initial infection and cause ongoing pathological effects. (106)  Spike protein therefore plays a crucial role in neurological complaints after SARS-CoV-2 infection, but also after the spike protein derived from novel gene-based anti-SARS-CoV-2 products(111) 

PATHOGENIC SUMMARY

"Long COVID neurological manifestations appear to result from a complex network of pathophysiological processes that may include the following mechanisms, which can operate independently, concurrently, or in various combinations depending on individual patient factors."

1. Initial Trigger: Prolonged virus/spike protein persistence and delayed clearance
2. Immune Activation: Immune dysregulation and autoantibody formation
3. Barrier Breakdown: Blood-brain barrier disruption, allowing inflammatory infiltration
4. Neuroinflammation: Microglial activation and NLRP3 inflammasome responses
5. Vascular Injury: Endothelial dysfunction and microclot formation
6. Structural Damage: White matter alterations and connectivity disruption
7. Metabolic Dysfunction: Galectin-9 elevation and gut-brain axis disruption
8. Cellular Damage: Mitochondrial dysfunction and oxidative stress
9. Autonomic Failure: Dysautonomia and Small Fiber Neuropathy
10. Self-Perpetuation: Integrated pathogenic networks maintaining chronic dysfunction
11.  Amyloid and other prion formation

Each step amplifies subsequent mechanisms, creating self-reinforcing pathological cycles that sustain neurological symptoms long after initial clearance of the infection.

• 1: VIRUS/SPIKE PROTEIN PERSISTENCE AND PROLONGED CLEARANCE

  1.1 Extended Viral RNA Clearance During Acute Phase

  • Delayed Upper Respiratory Tract Clearance: In a prospective cohort study of 73 non-hospitalized adults with SARS-CoV-2 infection, participants who developed brain fog and muscle pain at 90+ days post-infection demonstrated significantly delayed viral RNA clearance during the acute phase. Specifically, failure to clear viral RNA within 28 days of acute illness onset was associated with increased risk of subsequent brain fog (adjusted risk ratio 0.46, 95% CI 0.22-0.95) and muscle pain (adjusted risk ratio 0.28, 95% CI 0.08-0.94) in the post-acute period [2]
  • Acute Phase Viral Kinetics: Viral RNA clearance was assessed through serial sampling of mid-turbinate nasal and saliva specimens collected up to 9 times within the first 45 days after enrollment. The median time to viral RNA clearance was 17 days for participants achieving clearance within 21 days, with distinct viral RNA decay trajectories observed between those who subsequently developed brain fog versus those who did not [2]
  • Long-term Follow-up: Symptom assessment was conducted at 1, 3, 6, 12, and 18 months post-diagnosis using a comprehensive 49-symptom survey, with 40% of participants meeting the study's definition of long COVID [2]

  *  It has been shown that SARS-CoV-2 RNA can persist in the human body for up to 230 days after the onset of COVID-19 symptoms, including the brain (Stein et al., 2022). 

  1.2 Anatomical Sites of Persistence of Spike Protein

  1.2.1 Post-mortem Tissue Analysis

  
  

  PASC-positive individuals often show persistent or elevated levels of circulating spike protein for up to a year or longer after acute infection (Craddock et al., 2023; Schultheiß et al., 2023; Swank et al., 2023, Patterson B  2025, Rong Z 2024, Bhattacharjee B 2025, Ota N 2025, Yonker LM 2023 ). This suggests that the spike protein may be stored in cellular reservoirs, released into the bloodstream, and subsequently absorbed by other regions, potentially causing complications through endothelial damage and multiple other mechanisms reviewed below. (Cao et al., 2023).  

  • Skull-Meninges-Brain Axis Persistence: Using optical clearing and imaging techniques, both SARS-CoV-2 spike and nucleocapsid proteins were detected in post-mortem skull, meninges, and brain tissue samples from COVID-19 patients. Critical finding: spike protein was detected in 8 of 16 brain cortex samples and nucleocapsid protein in 3 of 16 brain cortex samples that were all PCR-negative for viral RNA, demonstrating protein persistence beyond active viral replication. The study included samples with an average post-mortem interval of 5 days, though specific timelines from initial infection to death were not uniformly reported [3]
  • Quantitative Distribution: In post-mortem analysis, spike protein was detected in approximately 2.3% of skull marrow cells, 2.8% of meningeal cells, and 1% of brain tissue cells across four COVID-19 patients. Both spike and nucleocapsid proteins were identified in skull marrow niches and meninges through confocal imaging. Spike protein colocalized with pericytes and was found in proximity to neurons in brain cortex samples, including colocalization with tyrosine hydroxylase-positive neurons [3]
  • Viral RNA vs. Protein Discordance: A critical pathogenic finding was that all brain cortex samples were PCR-negative for viral RNA, yet viral proteins (both spike and nucleocapsid) were detectable, suggesting either specific protein uptake mechanisms to the brain or longer half-life of viral proteins compared to viral particles [3]

  The toxic properties of spike protein can account for many of the neurological symptoms following SARS-CoV-2 infection and after injection of mRNA COVID vaccinations. . Spike protein easily crosses the BBB and  interferes with ACE2 receptors, various neurotransmitters and acts on different cells, tissues and organs.. Such spike protein associated pathologies (spikeopathies) can  further neurological proteinopathies with thrombogenic, neurotoxic, neuroinflammatory and neurodegenerative potential for the human nervous system, particularly the central nervous system. The potential neurotoxicity of spike protein  needs to be critically examined, as the mRNA COVID vaccinations have been administered to millions of people worldwide.  We do not know what the long term effects will be.  (103)

  1.2.2 Living Patient Tissue Analysis

  • Multi-organ Tissue Distribution: In a cross-sectional study of 225 patients who recovered from mild COVID-19, viral RNA was detected in 16 (30%) of 53 solid tissue samples at 1 month, 38 (27%) of 141 samples at 2 months, and 7 (11%) of 66 samples at 4 months post-infection. Viral RNA was distributed across ten different types of solid tissues, including liver, kidney, stomach, intestine, brain, blood vessel, lung, breast, skin, and thyroid [40]
  • Long COVID Case Documentation: Case reports demonstrate persistence of SARS-CoV-2 nucleocapsid and spike proteins in appendix, skin, and breast tissues of long COVID patients at 163 and 426 days after symptom onset, with viral antigens co-localizing with macrophage markers CD68, CD14, CD206, and CD169 [41] 

  *A Japanese study found spike protein detected in cerebral arteries of 7 out of 16 vaccinated patients up to 17 months post vaccine. (Ota N 2025) 

  1.2.3 Plasma-based Antigen Detection

  • Persistent Circulating Antigens: In a controlled study of 171 pandemic-era participants compared to 250 pre-pandemic controls using single molecule array (Simoa) detection, SARS-CoV-2 antigens were detected at significantly elevated rates in the post-acute phase. The absolute difference in antigen prevalence was +10.6% (95% CI +5.0 to +16.2) at 3.0-6.0 months, +8.7% (+3.1 to +14.3) at 6.1-10.0 months, and +5.4% (+0.42 to +10.3) at 10.1-14.1 months post-infection [4]
  • Antigen-Specific Patterns: Among 660 pandemic-era specimens tested, 61 (9.2%) from 42 participants (25% of cohort) had detectable antigens. Spike protein was the most commonly detected antigen (5.0% of specimens), followed by S1 subunit (2.3%) and nucleocapsid protein (2.3%) [4]

  1.2.4 Cellular Reservoirs

  • Monocyte Persistence: In a study of 144 individuals including 64 chronic COVID patients, SARS-CoV-2 S1 protein was detected in CD14lo, CD16+ non-classical monocytes in 73% (19 of 26) of post-acute sequelae COVID-19 (PASC) patients up to 15 months post-infection. Mass spectrometry confirmation identified up to 44% of S1 subunit peptides in patient samples. Importantly, only fragmented SARS-CoV-2 RNA was detected, with no full-length viral sequences identified, indicating protein persistence without active viral replication [5]
  ● Elevated Monocyte Populations: Both intermediate (CD14+, CD16+) and non-classical monocytes (CD14lo, CD16+) were significantly elevated in PASC patients compared to healthy controls (P=0.002 and P=0.01, respectively) throughout the 15-month observation period [5]
  

GO TO TOP OF PAGE

• 2: IMMUNE DYSREGULATION AND AUTOANTIBODY FORMATION

  2.1 T Cell Exhaustion and Dysfunction

  2.1.1 SARS-CoV-2-Specific T Cell Exhaustion

  • Exhausted SARS-CoV-2-Specific CD8+ T Cells: SARS-CoV-2-specific CD8+ T cells from Long COVID patients more frequently expressed exhaustion markers PD-1 and CTLA-4 compared to recovered individuals at 8 months post-infection. This exhaustion pattern was specifically observed only in virus-specific CD8+ T cells, not in total CD8+ T cells, and is consistent with ongoing stimulation by viral antigens typically observed in chronic viral infections [42]
  • Tissue-Homing CD4+ T Cell Dysregulation: CD4+ T cells from Long COVID patients preferentially expressed elevated levels of tissue-homing chemokine receptors CXCR4, CXCR5, and CCR6. CXCR4+CXCR5+ and CXCR5+CCR6+ CD4+ T cell populations were significantly increased in Long COVID patients, suggesting ongoing tissue infiltration and sustained inflammatory responses [42]

  2.1.2 Neurological T Cell Dysfunction

  • Neuro-PASC T Cell Signatures: Patients with neurological post-acute sequelae demonstrate distinct immunological signatures including elevated humoral and cellular immune responses toward SARS-CoV-2 nucleocapsid protein at 6 months post-infection, enhanced virus-specific IL-6 production, and diminished CD8+ T cell activation. The severity of cognitive deficits correlates with reduced diversity of effector molecule expression in T cells [43]
  • Cerebrospinal Fluid T Cell Exhaustion: Direct cerebrospinal fluid analysis from patients with neurological COVID-19 manifestations reveals significant expansion of exhausted CD4+ T cells compared to other neuroinflammatory conditions, indicating dysfunctional T cell-driven antiviral immunity within the central nervous system [44]

  2.1.3 Chronic T Cell Activation and Senescence

  • Depletion of Naive Immune Cell Populations: Long COVID patients demonstrate complete absence of specific naive immune cell populations including naive CD8+ T cells and CD4+ T cells. These populations remain absent at 8 months post-infection, suggesting persistent conversion of naive cells into activated states [45]
  • Enhanced T Cell Exhaustion Markers: Long COVID patients show significantly higher expression of exhaustion markers PD-1 and TIM-3 on CD8+ T cells at both 3 and 8 months post-infection, indicating chronic T cell activation and potential exhaustion [45]
  • Persistent Interferon Responses: Long COVID patients demonstrate persistently elevated levels of type I interferon (IFN-β) and type III interferon (IFN-λ1) that remain significantly elevated at 8 months post-infection. IFN-β levels were 7.32-fold higher in Long COVID patients compared to controls [45]
  • Severity-Dependent T Cell Polarization: Severe COVID-19 convalescents demonstrate persistent polarization toward exhausted/senescent states of both CD4+ and CD8+ T cells. CD8+ T cells exhibit high proportions of CD57+ terminal effector cells (reaching 40% of total CD8+ T cells) at 6 months post-infection, decreased naive cell populations, and augmented granzyme B and IFN-γ production, indicating unresolved immune activation persisting throughout the post-acute period [46]
  • Miscoordinated Adaptive Immunity: Long COVID manifests with uncoordinated adaptive immune responses characterized by elevated SARS-CoV-2 antibody levels but loss of positive correlation between humoral and cellular immune responses that was present in recovered individuals. This fundamental dysregulation in adaptive immune crosstalk includes elevated yet dysregulated TH2 responses [42]

  2.2 Complement System Activation

  2.2.1 Complement Activation in Long COVID

  • Persistent Complement Activation: Large-scale proteomic analysis of 657 post-hospitalized participants reveals elevated markers of complement activation as core features across all Long COVID symptom groups. C1QA (complement component 1Q subcomponent subunit A) is significantly elevated in patients with cognitive impairment and gastrointestinal symptoms, indicating persistent complement activation months after acute infection [47]

  2.2.2 Complement-Mediated Immune Dysregulation

  • Complement-Autoantibody Interactions: Immune complexes activate the classical complement pathway, targeting endothelial cells and platelets to initiate antibody-mediated vascular injury [9]
  • Microglial Complement Dysregulation: Brain-resident microglia serve as the primary source of complement components (C1q, C3, C4) within the central nervous system and express comprehensive complement receptor profiles. Complement stimulation of microglial C5aR1 supports pro-inflammatory effector responses including IL-6 and TNF production through p38 and ERK1/2-dependent pathways [48]

  2.3 Myeloid Cell Dysregulation

  2.3.1 Myeloid Inflammation Signatures

  • Myeloid Inflammation Signatures: Proteomic profiling reveals that myeloid inflammation markers including IL-1R2 and CSF3 (G-CSF) are consistently elevated across Long COVID phenotypes. CSF3 promotes neutrophilic inflammation, with the strongest association observed between myeloid inflammation markers and cognitive fatigue [47]
  • Persistent Myeloid Cell Activation: Highly activated CD38+HLA-DR+ myeloid cells, activated CD14+CD16+ monocytes, and plasmacytoid dendritic cells expressing activation markers CD86 and CD38 remain elevated in Long COVID patients at both 3 and 8 months post-infection, indicating sustained innate immune activation [45]
  • Monocyte Transcriptional Reprogramming: Single-cell RNA sequencing identifies specific gene expression changes in monocyte populations, including dysregulation of PPIE (peptidylprolyl isomerase E). Gene Ontology pathway analysis reveals significant alterations in transcriptional regulation, splicing, protein regulation, and neutrophil degranulation pathways [42]

  2.3.2 Inflammatory Cytokine Networks

  • Pro-inflammatory Cytokine Elevation: Plasma proteomics reveals elevated expression of inflammatory mediators including LGALS9, TNF, CXCL10, and CD48 in Long COVID patients [42]
  • Persistent Systemic Inflammation: Long COVID patients demonstrate persistent elevation of inflammatory markers creating a sustained inflammatory state that correlates with neurological symptom severity [10]

  2.33 Elevated IgG4 antibodies 

  Several recent studies have reported that vaccination with mRNA based 19 Covid-19 vaccines can lead to elevated levels of Spike-specific IgG4 (Akhtar et al., 2023; Buhre et al.2022, Gelderloos et al., 2024; Irrgang et al., 2023, Tam J 2025 ) Antigen-specific IgG4 has been reported in the context of allergy (Qin et al., 2022) and autoimmunity

  
  

  Tam J Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses bioRxiV 2025 

  
  
  
  
  

   Elevated IgG 4 2.4 Latent Viral Reactivation

  2.4.1 Epstein-Barr Virus Reactivation

  • EBV Reactivation in Long COVID: Studies demonstrate EBV reactivation in 27.1% of COVID-19 patients compared to 12.5% in controls, occurring due to COVID-19-induced T-cell exhaustion and functional impairment. Multi-omic studies identify EBV viremia as one of four main risk factors for Long COVID development alongside type-2 diabetes, SARS-CoV-2 RNAemia, and specific autoantibodies [6, 49]
  • Mechanistic EBV-SARS-CoV-2 Interaction: EBV lytic replication promotes ACE2 expression on host cells, facilitating SARS-CoV-2 cellular entry and creating synergistic infection dynamics. The EBV transcriptional activator Zta directly activates methylated ACE2 promoters, leading to enhanced ACE2-dependent SARS-CoV-2 pseudovirus entry in EBV-infected epithelial cells [55]. Bioinformatics analysis of RNA-seq data from long COVID patients reveals common pathogenic gene expression patterns between EBV reactivation and long COVID, supporting mechanistic connections between these conditions [50]

  2.4.2 Multiple Herpesvirus Reactivation

  • Broad Herpesvirus Family Activation: Reactivation of cytomegalovirus, herpes simplex virus 1, human herpesvirus 6, and human herpesvirus 7 contributes to chronic immune dysregulation [6]

  2.5 Autoantibody Formation and Neurological Targeting

  2.5.1 Nervous System-Specific Autoantibodies

  
  

  Researchers at Yale and the Icahn School of Medicine investigated the role of autoantibodies in the development of neurological symptoms associated with long COVID.   (Bhattacharjee B 2025)

  In another study when researchers gave healthy mice antibodies from patients with Long COVID, some of the animals began showing Long COVID symptoms—specifically heightened pain sensitivity and dizziness. It is among the first studies to offer enticing evidence for the autoimmunity hypothesis.  This study suggests at least some of the symptoms of Long COVID are driven by autoimmunity.   (K Santos Guedes de Sa et al 2024)

  Multiple studies now show that a primary mechanism implicated in long COVID is the persistence of autoantibodies and persistent immune activation. The authors point out that 10–12% of vaccinated cases develop long COVID ( Sun D Feb 2025)

  • Comprehensive Autoantigen Targeting: Using protein arrays containing over 21,000 human proteins, elevated autoantibodies targeting nervous system proteins are specifically identified in Long COVID patients with neurocognitive and neurological symptoms. These autoantibodies demonstrate specificity for central and peripheral nervous system components [1]
  • Functional Pathogenic Autoantibodies: Purified IgG from Long COVID patients demonstrates cross-reactivity with human pons tissue and mouse sciatic nerves, spinal cord, and meninges. Passive transfer of patient IgG into mice reproduces neurological symptoms including increased pain sensitivity, loss of balance, and coordination deficits, directly demonstrating autoantibody pathogenicity [1]
  • Autonomic Nervous System Autoantibodies: Autoantibodies targeting β1 and β2 adrenergic receptors and M3 and M4 muscarinic acetylcholine receptors are significantly elevated in Long COVID patients. Concentrations of these autoantibodies correlate with neurological dysfunction severity including impaired psychomotor speed, visual search, attention, and fatigue [8] 
  • ACE2-Specific Autoantibodies: In one study of 67 patients with known SARS-CoV-2 infection, anti-ACE2 autoantibodies were detected in 81% (26/32) of convalescent patients and 93% (14/15) of acutely hospitalized patients, compared to none of the 13 uninfected controls. In this cohort, patients with ACE2 autoantibodies demonstrated significantly reduced soluble ACE2 activity in plasma (median activity 263 vs 1056 pmol/min/ml in those without autoantibodies, p<0.01). The study authors hypothesize that these autoantibodies may disrupt the brain renin-angiotensin system, potentially leading to increased angiotensin II levels and enhanced AT1 receptor activation, which could contribute to neuroinflammation observed in some Long COVID patients [51] There are multiple studies now showing lingering autoantibodies to GPCRs including the ACE 2 receptor.   GPCRs are a large family of membrane-bound metabotropic receptors that play a role in many physiological processes, from responses to neurotransmitters and environmental stimuli, to responses to hormones.  G protein-coupled receptors (GPCRs) are implicated in the development of dysautonomia, particularly postural orthostatic tachycardia syndrome (POTS).   These receptors are distributed in different brain regions, including the cortex, amygdala, and hippocampus, and are associated with learning and memory.   (Belluci 2024) 

  * Neuronal targets:   Almulia et al showed that autoimmune responses directed at neuronal proteins play a key role in Long COVID disease. Brain reactive autoantibodies directed at MBP, MOG, tubulin, CP2, and synapsin are elevated in patients with Long COVID disease indicating a neuro-autoimmune pathophysiology of this condition.  

  Synapsin I autoantibodies, previously identified in individuals with neurological disorders, have been demonstrated to modulate synaptic transmission and influence neuronal synaptic density 

  Elevated levels of autoantibodies against MOG have been detected in various demyelinating conditions, encompassing optic neuritis, transverse myelitis, acute disseminated encephalomyelitis, and cerebral cortical encephalitis.

  Alterations in αβ-tubulin dimers and γ-tubulin have been implicated in brain malformations and are recognized contributors to cognitive dysfunctions 

  A study by Arit F 2025,  showed high serum prevalence of autoreactive IgG antibodies against peripheral nerve structures in patients with neurological post-COVID-19 vaccination syndrome

  
  
  
  

  2.5.2 Molecular Mimicry Mechanisms Targeting Neural Tissues

  
  

  Molecular mimicry is one of the leading mechanisms by which infectious or chemical agents may induce autoimmunity. It occurs when similarities between foreign and self-peptides favor an activation of autoreactive T or B cells by a foreign-derived antigen in a susceptible individual.

  There is a high degree of structural homology between spike protein and the human proteome  (molecular mimicry), which may cause a cross-reaction after COVID and with vaccine-induced immune responses

  Molecular mimicry may explain multi-organ damage in COVID and in Long Haulers and vaccine injuries. 

  
  
  
  
  • SARS-CoV-2-Host Sequence Homology: Systematic review of experimentally validated mimicking sequences reveals that molecular mimicry and immunological cross-reactivity may account for autoantibody development following SARS-CoV-2 infection. Analysis of linear human epitope sequences through the Immune Epitope Database demonstrates that molecular mimicry and immunological cross-reactivity is central to the loss of immunological tolerance during SARS-CoV-2 infection, though most evidence is based on bioinformatics approaches with limited demonstration of direct immunological cross-reactivity [52]
  • EBV-Mediated Molecular Mimicry: EBV reactivation contributes to autoimmunity through molecular mimicry mechanisms, where reactivated EBV antigens cross-react with host autoantigens. Anti-EBNA-1 (Epstein-Barr nuclear antigen 1) antibodies demonstrate cross-reactivity with human proteins [7, 53]

  2.5.3 Persistent Neurological Autoimmune Responses

  • Persistent Autoantibody Formation: Comprehensive 16-month longitudinal analysis demonstrates that new-onset autoantibodies against diverse antigens emerge following SARS-CoV-2 infection and remain elevated for at least 12 months. The prevalence increases with COVID-19 severity, with distinct autoantibody patterns associated with specific neuropsychiatric symptoms [54]

  2.6 Integrated Immune System Dysregulation

  • Adaptive Immunity Dyscoordination: Long COVID patients exhibit fundamental disconnection between humoral and cellular immune responses. While Long COVID individuals had significantly higher (2.3×) total receptor binding domain-specific antibody titers compared to recovered individuals, they demonstrated loss of coordinated immune responses. This immune dyscoordination includes elevated yet dysregulated TH2 responses [42]
  • Elevated Inflammatory Mediator Profile: Long COVID patients exhibit elevated levels of inflammatory mediators including TNF and CXCL10. Long COVID individuals showed higher proportions of CD4+ central memory T cells and regulatory T cells compared to recovered individuals [42]
  ● Transcriptional Immune Reprogramming: Single-cell analysis reveals dysregulated genes including THEMIS (involved in T cell development and selection) and NUDT2 (nucleotide metabolism) in CD8+ T cells, and PPIE in monocytes, indicating broad transcriptional reprogramming of immune responses [42]

GO TO TOP OF PAGE

3: BLOOD-BRAIN BARRIER DISRUPTION

3.1 PERSISTENT BBB DYSFUNCTION IN LONG COVID

3.1.1 Temporal Characteristics and Regional Distribution

Long-term BBB Persistence:

• Dynamic Contrast-Enhanced MRI Evidence: Dynamic contrast-enhanced MRI demonstrates persistent BBB hyperpermeability extending up to 7 months post-SARS-CoV-2 infection, with evidence of continued dysfunction at one-year follow-up, specifically in individuals with brain fog. These findings were demonstrated in a cohort of 32 participants (10 recovered, 11 long COVID without brain fog, 11 long COVID with brain fog) using dynamic contrast-enhanced MRI with quantifiable regional specificity [10]
• Regional Specificity: Regional specificity occurs with disruption concentrating in bilateral temporal lobes and bilateral frontal cortex, with temporal lobe involvement correlating with anosmia duration [10]
• Quantified Regional Differences: Quantification of regional BBB permeability demonstrates significant differences in temporal and frontal cortical regions in brain fog patients [10]

Temporal Dynamics of BBB Markers:

• Persistent Elevation Beyond Acute Phase: BBB biomarkers show persistent elevation beyond 4 weeks after infection, distinguishing post-COVID syndrome from acute phase [56]
• Severity-Dependent Persistence: BBB disruption biomarkers (MMP-9, GFAP) demonstrate distinct temporal profiles, with MMP-9 reaching highest levels in acute phase neurological COVID patients and showing severity-dependent persistence in long-term follow-up [56]
• Reduced Cerebrovascular Reactivity: Transcranial Doppler studies demonstrate reduced cerebrovascular reactivity persisting 300 days post-infection, indicating sustained BBB endothelial dysfunction [11]

3.1.2 Biomarker Patterns

TGF-β as Brain Fog-Specific Marker:

• Specific Elevation in Brain Fog: TGF-β is specifically elevated in patients with brain fog compared to long COVID patients without neurological symptoms [10]
• Correlation with Structural Changes: TGF-β demonstrates significant correlation with BBB disruption and structural brain changes, correlating with BBB dysfunction percentage, CSF volume, brainstem volume, and amygdala volume [10]

Astrocytic Dysfunction Markers:

• S100β Elevation: S100β elevation indicates BBB leakage and astrocytic dysfunction in patients reporting brain fog [10]
• Severe Biomarker Elevation: Combined elevation of MMP-9, GFAP, and NFL in COVID-19 patients reaches levels comparable to severe neurodegenerative disease (ALS), indicating substantial BBB compromise across disease severity spectrum [56]
• GFAP as Barrier Dysfunction Marker: GFAP levels reflect astrocytic damage and BBB dysfunction in long COVID patients [56]

3.2 PATHOGENIC MECHANISMS OF BBB DISRUPTION

3.2.1 Immune-Mediated Barrier Dysfunction

Transcriptomic and Cellular Evidence:

• Coagulation System Dysregulation: Transcriptomic analysis reveals dysregulation of coagulation systems and dampened adaptive immune responses in individuals with brain fog [10]
• Enhanced Immune Cell Adhesion: Peripheral blood mononuclear cells from long COVID patients demonstrate increased adhesion to human brain endothelial cells in vitro [10]
• Serum-Induced Endothelial Activation: Brain endothelial cell exposure to serum from long COVID patients induces dose-dependent upregulation of inflammatory adhesion molecules, with significant increases in TNF (P = 0.0006) and VCAM1 (P < 0.0001) expression [10]
• Sustained Inflammatory Profile: Sustained systemic inflammation with elevated IL-8, GFAP, and TGF-β characterizes long COVID-associated brain fog [10]

For comprehensive immune system dysregulation, complement activation, and autoantibody formation mechanisms, see Section 2

3.2.2 Matrix Metalloproteinase-Mediated Degradation

MMP-9 Activation and Effects:

• Persistent MMP-9 Elevation: Elevated MMP-9 levels persist in severe neurological COVID cases during long-term follow-up [56]
• Degradation Mechanisms: MMP-9 disrupts BBB integrity by degrading underlying tight junction complexes and collagen IV in basement membranes [11, 56]
• Pericyte-Mediated MMP-9 Production: Pericytes constitute the primary source of MMP-9 within the neurovascular unit. Inflammatory stimuli rapidly activate MMP-9 at pericyte somata, resulting in degradation of underlying tight junction complexes and basement membrane components, establishing pericytes as primary mediators of BBB disruption [56]

PPIA-CD147-MMP-9 Signaling Axis:

• PPIA as MMP-9 Activator: Peptidyl prolyl cis-trans isomerase A (PPIA) acts as an MMP-9 activator through binding to CD147 receptor [56]
• Differential Expression Patterns: NeuroCovid patients display lower PPIA levels but higher MMP-9 levels compared to ICU COVID patients [56]

3.2.3 Basement Membrane Disruption

Basement Membrane Disruption Mechanism:

• Transcellular Crossing Mechanism: SARS-CoV-2 crosses the blood-brain barrier accompanied by basement membrane disruption without tight junction alteration [57]
• Collagen IV Degradation: MMP-9 up-regulation mediates collagen IV degradation in basement membranes [57]

Preserved Tight Junction Integrity:

• Intact Junction Proteins: Tight junction proteins claudin-5, ZO-1, and occludin demonstrate preserved expression and mRNA levels following SARS-CoV-2 infection [57]
• Preserved Ultrastructure: Transmission electron microscopy reveals intact tight junction ultrastructure in infected animals [57]
• Transcellular Transport Pathway: These findings indicate that SARS-CoV-2 crosses the BBB via transcellular rather than paracellular pathways [57]

3.2.4 Transcellular BBB Crossing Mechanism

SARS-CoV-2 Endothelial Cell Mechanism:

• Direct Endothelial Infection: SARS-CoV-2 traverses the BBB through transcellular transport mechanisms involving direct infection of brain microvascular endothelial cells, confirmed by basal chamber viral RNA detection in vitro [57]
• In Vitro Confirmation: In vitro BBB models demonstrate viral RNA detection in the basal chamber, confirming transcellular transport capability [57]

3.2.5 Genetic Susceptibility to BBB Dysfunction

Host Genetic Factors:

• FOXP4 Gene Variants: FOXP4 gene variants may influence BBB susceptibility, as FOXP4 is crucial for central nervous system development with mutations associated with neurodevelopmental disorders [11]
• Individual Variability Factors: Genetic predisposition factors may contribute to individual variability in BBB vulnerability following SARS-CoV-2 infection [11]

3.3 CELLULAR MECHANISMS IN NEUROVASCULAR UNIT DYSFUNCTION

3.3.1 Neurovascular Unit Components

Structural Organization:

• Component Composition: The BBB comprises brain endothelial cells, vascular basement membrane, pericytes, astrocyte end-feet, microglia, and neurons, collectively forming neurovascular units [59]
• Receptor Expression: Endothelial cells, pericytes, and astrocytes highly express ACE2, indicating BBB susceptibility to SARS-CoV-2-induced derangements of tight junction and adherens junction proteins [59]

3.3.2 Endothelial Cell Dysfunction

Endothelial Cell Infection Capability:

• Spike Protein Effects: Spike protein induces dose-dependent endothelial cell activation with increased TNF, TGF-β, ICAM1, and VCAM1 expression [10] Spike protein damages the BBB (Buzhdygan T)
• Infection Mechanism: SARS-CoV-2 demonstrates capability to infect brain microvascular endothelial cells, establishing the mechanism for transcellular BBB crossing [57]

3.3.3 Astrocytic End-Feet Dysfunction

Functional Roles and Damage:

• Structural Function: Astrocytic end-feet contain GFAP and express aquaporin 4, facilitating water homeostasis regulation and neurotransmitter clearance [56, 59]
• Damage Biomarkers: High blood GFAP concentrations reflect damage to astrocytic end-feet enveloping the BBB, with GFAP released directly into blood when BBB is injured [56]
• Inflammatory Role: Astrocytic end-feet attach directly to endothelium and vasculature, playing significant roles in neuroinflammatory responses [59]

3.3.4 Pericyte Involvement

Structural and Functional Roles:

• Vascular Control: Pericytes act as contractile components in brain microvascular BBB, responding to astrocyte inputs and regulating capillary diameter and blood flow [59]
• Direct Viral Involvement: Post-mortem analysis demonstrates SARS-CoV-2 spike protein presence in brain pericytes, with specific colocalization with PDGFR+ pericytes, confirming direct cellular involvement in BBB disruption [3]
• Pathological Implications: Pericyte damage has implications for neurodegenerative disorders, dementia, stroke, and other brain disorders [59]

3.4 INTEGRATION WITH LONG COVID PATHOGENESIS

3.4.1 Connection to Viral Persistence (Section 1)

Spike Protein Persistence Effects:

• Sustained Barrier Disruption: Persistence of viral components, particularly spike protein, contributes to BBB disruption through sustained interaction with endothelial cells and pericytes [10]
• Monocyte-Mediated Effects: SARS-CoV-2 S1 protein has been detected in CD16+ non-classical monocytes up to 15 months post-infection, with mass spectrometry confirmation in 73% of long COVID patients, providing a potential ongoing stimulus for barrier dysfunction [5]

For detailed mechanisms of viral persistence and spike protein distribution, see Section 1

3.4.2 Link to Immune Dysregulation (Section 2)

Inflammatory Infiltration Pathway:

• Immune Cell Extravasation: BBB disruption enables extravasation of serum components and facilitates immune cell infiltration into brain parenchyma [10]
• Autoantibody Access: Compromised barrier function allows inflammatory mediators and autoantibodies to access previously protected neural tissue [10]

For comprehensive immune system dysregulation and autoantibody formation mechanisms, see Section 2

3.4.3 Preparation for Neuroinflammation (Section 4)

Gateway for Microglial Activation:

• Inflammatory Mediator Access: BBB disruption creates the anatomical prerequisite for microglial activation by allowing systemic inflammatory mediators to enter brain tissue [10]
• Immune Cell Infiltration: Compromised barrier integrity enables immune cell infiltration that triggers sustained neuroinflammatory responses [10]

For detailed neuroinflammation and microglial activation mechanisms, see Section 4

3.4.4 Connection to Vascular Dysfunction (Section 5)

Cerebrovascular Interface:

• Endothelial Dysfunction Manifestation: BBB disruption represents the neurological manifestation of systemic endothelial dysfunction characteristic of long COVID [10]
• Fibrinogen-Mediated Effects: Elevated fibrinogen levels during acute COVID-19 predict subsequent cognitive deficits through mechanisms requiring BBB compromise for brain tissue access [58]

For comprehensive vascular dysfunction and microclot formation mechanisms, see Section 5

3.5 FIBRINOGEN AND BBB INTERFACE

3.5.1 Clinical Predictive Evidence and BBB Compromise

Large-Scale Clinical Findings:

• Predictive Biomarker Evidence: Prospective cohort study of 1,837 adults hospitalized with COVID-19 demonstrates that elevated fibrinogen relative to C-reactive protein during acute admission predicts both objective and subjective cognitive deficits at 6 and 12 months post-infection [58]
• Cognitive Association: Elevated fibrinogen relative to C-reactive protein significantly associates with lower Montreal Cognitive Assessment scores and higher cognitive symptom questionnaire scores at both 6 and 12 months post-infection [58]
• Clinical Significance: Individuals in the top half of the fibrinogen profile demonstrate mean cognitive symptom scores of 2.52 versus 1.79 for the bottom half (difference 0.72, 95% CI 0.52–0.93), representing clinically meaningful cognitive impairment on the 7-point scale. Additional measurements show lower MoCA scores at 6 months (difference 0.66, 95% CI 0.34–0.98) and 12 months (difference 0.63, 95% CI 0.13–1.12) [58]

Mechanistic Requirements:

• Hypercoagulopathy Specificity: The specificity for fibrinogen elevation relative to C-reactive protein supports the hypothesis that this biomarker profile results from hypercoagulopathy rather than acute inflammatory responses [58]
• BBB Dependence: Fibrinogen can only access brain parenchyma when blood-brain barrier integrity is compromised, establishing the mechanistic connection between BBB disruption and fibrinogen-mediated cognitive dysfunction. Results were robust across secondary analyses and replicated in an independent large-scale electronic health records dataset [58]

3.5.2 Post-mortem Evidence

Direct BBB Compromise Evidence:

• Fibrinogen Extravasation: Brain sections from COVID-19 patients show fibrinogen extravasation and coagulation system dysregulation, providing direct evidence of BBB compromise [10]
• Spatial Transcriptomics: Spatial transcriptomics reveals serum protein extravasation specifically at the neurovascular interface, confirming barrier breakdown [10]
• Microvascular Injury: Microvascular injury includes fibrinogen leakage through compromised endothelial barriers [10]

3.5.3 Neurological Consequences

Functional Impact:

• Neuroinflammatory Contribution: Fibrinogen extravasation into brain parenchyma contributes to neuroinflammation and neurological symptom development [10]
• Direct Neuronal Impact: Serum protein leakage through disrupted BBB directly impacts neuronal function and contributes to cognitive impairment [10]
• Mechanistic Requirement: Elevated fibrinogen levels during acute COVID-19 associate with subsequent cognitive deficits through mechanisms that require blood-brain barrier compromise, as fibrinogen can only access brain parenchyma when barrier integrity is disrupted [58]

For comprehensive vascular dysfunction and systemic microclot formation mechanisms, see Section 5

GO TO TOP OF PAGE

4: NEUROINFLAMMATION AND MICROGLIAL ACTIVATION

4.1 Direct Microglial Infection

4.1.1 SARS-CoV-2 Microglial Infection

• Direct Viral Infection: SARS-CoV-2 can directly infect human microglial cell models, including the HMC3 immortalized cell line, iPSC-derived microglia, and primary human brain microglial cells, as demonstrated by viral RNA detection and neutralizing antibody inhibition studies. In the HMC3 model, infection elicits M1-like proinflammatory responses characterized by IL-1β, IL-6, and TNF-α production, followed by cytopathic effects with progressive cell death beginning at 4 days post-infection. RNA sequencing analysis reveals that endoplasmic reticulum stress and immune responses are induced in the early phases (3 days post-infection), while apoptotic processes dominate in the late phases (6 days post-infection) of viral infection. In vivo studies using K18-hACE2 transgenic mice confirmed viral spike protein colocalization with Iba1+ microglia in brain tissue, supporting the potential for microglial infection during SARS-CoV-2 neuroinvasion [12]

4.1.2 Spike Protein-Mediated Microglial Activation

• Direct Spike Protein Effects: SARS-CoV-2 spike protein directly activates human microglia, triggering the release of distinct proinflammatory mediators through two receptor pathways: full-length spike protein stimulates TLR4-dependent secretion of IL-1β and CXCL8 from microglia, while the receptor-binding domain activates ACE2-dependent release of IL-18, TNF-α, and S100B from these same cells. This spike protein-induced microglial activation leads to sustained proinflammatory responses and microglial-mediated synaptic elimination. Additionally, SARS-CoV-2 infection causes brain vascular damage and endothelial dysfunction [13]

4.1.3 NLRP3 Inflammasome Activation

• Spike Protein-Mediated Inflammasome: Spike protein-mediated inflammasome activation is significantly enhanced by α-synuclein fibrils and completely abolished by NLRP3 inhibition [14]
• Cytokine Processing: Activated inflammasome cleaves pro-IL-1β and pro-IL-18 into mature forms with concurrent caspase-1-dependent pyroptotic cell death [14, 15]

4.2 Neuroimaging Evidence of Persistent Microglial Activation in Long COVID

4.2.1 TSPO PET Neuroinflammation Biomarkers

• Quantitative TSPO Elevation: Translocator protein positron emission tomography demonstrates significantly elevated TSPO total distribution volume in Long COVID patients with persistent depressive and cognitive symptoms following initially mild to moderate COVID-19 illness. In a case-control study of 40 participants (20 COVID-DC vs 20 healthy controls), TSPO VT showed 20% elevation in dorsal putamen and 22% elevation in ventral striatum compared to healthy controls, with measurements taken 0-24 months post-infection (60% scanned within 0-6 months, 40% within 7-24 months post-infection). TSPO VT in dorsal putamen negatively correlates with motor speed (r=-0.53), with the 10 participants showing the slowest motor speed having 27% higher dorsal putamen TSPO VT than healthy controls. The study utilized [18F]FEPPA PET with validated 2-tissue compartment modeling for quantitative TSPO measurement [60]
• Clinical Symptom-Neuroinflammation Correlation: The study population demonstrated prominent Long COVID symptoms including universal anhedonia (n=20/20), motor speed slowing (n=19/20), energy problems attributed to low motivation (n=18/20), and cognitive concerns (n=16/20 scoring above 33 on the Cognitive Failures Questionnaire). These symptom profiles directly correlate with the regional TSPO elevation patterns, supporting the mechanistic role of striatal neuroinflammation in Long COVID neurological manifestations. The correlation between dorsal putamen TSPO VT and finger-tapping performance provides direct evidence linking regional neuroinflammation to functional cognitive-motor deficits in Long COVID. Study authors concluded that gliosis may be consequent to inflammation, injury, or both, particularly in the ventral striatum and dorsal putamen, which may explain persistent depressive and cognitive symptoms in Long COVID [60]
• Multi-regional Microglial Activation: [11C]PBR28 PET imaging reveals significantly elevated microglial activation across midcingulate cortex, anterior cingulate cortex, corpus callosum, thalamus, basal ganglia, and at the boundaries of ventricles in post-acute sequelae of COVID-19 patients [61]
• Neuroinflammation-Vascular Dysfunction Correlations: Significant positive correlations between PET signal and seven plasma vascular health markers: fibrinogen (r=.80, p=.0032), α2-macroglobulin (r=.73, p=.011), orosomucoid (r=.69, p=.019), fetuin A (r=.68, p=.022), sL-selectin (r=.70, p=.025), pentraxin-2 (r=.66, p=.026), and haptoglobin (r=.74, p=.015). This provides direct evidence that neuroinflammation and vascular dysfunction are mechanistically linked in Long COVID pathogenesis [61]

4.2.2 Regional Distribution in COVID-19 Neuroinflammation

• Microglial Reactivity Pattern: Preclinical studies demonstrate that mild SARS-CoV-2 infection in mouse models induces microglial reactivity with elevated CCL11 levels, correlating with cognitive dysfunction and impaired neurogenesis. Clinical observations in Long COVID patients following mild acute infections reveal multilineage cellular dysregulation and myelin loss, with microglial reactivity patterns resembling those observed in chemotherapy-related cognitive impairment [16]
• Hippocampal and Medullary Involvement: In hamster models of SARS-CoV-2 infection, microglial reactivity specifically targets the hippocampus and inferior olivary nuclei (ION) of the medulla. IBA1+ activated microglia in the hippocampus peak at 5 days post-infection (dpi), while ION shows larger microglial cell bodies and thicker processes that remain elevated from 4 to 14 dpi. Human post-mortem hippocampal tissue from COVID-19 patients confirmed similar patterns of microglial activation and neuroinflammation, validating the animal model findings [18]
• Temporal Dynamics of COVID-19 Neuroinflammation: Hippocampal IL-1β levels increase at 2 dpi, peak at 5 dpi, then gradually decrease to baseline by 14 dpi, demonstrating the temporal evolution of neuroinflammatory responses in acute COVID-19. However, while these hamster studies demonstrate recovery by day 14, the persistence of neuropsychiatric symptoms in Long COVID suggests prolonged neuroinflammation in human patients that may extend well beyond the acute recovery phase observed in animal models [18]

4.2.3 COVID-19 Neurogenesis Disruption

• Adult Neurogenesis Loss: COVID-19 induces loss of hippocampal neurogenesis that contributes to neuronal dysfunction and neurocognitive symptoms. Decreased expression of doublecortin, a marker of neuroblasts and immature neurons, occurs in both COVID-19 hamster models and human post-mortem hippocampal tissue. Human post-mortem analysis confirmed morphological changes in pyramidal cells, increased apoptosis, and reduced neurogenesis in the dentate gyrus, supporting the clinical relevance of animal model findings for understanding Long COVID cognitive sequelae [18]

4.3 Sustained Inflammatory Mediator Production in Long COVID

4.3.1 Persistent Cytokine Triad in Long COVID

• IL-1β, IL-6, and TNF-α Elevation: Long COVID patients demonstrate persistent elevation of the inflammatory cytokine triad (IL-1β, IL-6, and TNF-α) at 8 months post-infection in primary cohort and 10 months in validation cohort, specifically associated with neuropsychiatric symptoms. This triad shows positive correlation with each other in individual patients, creating self-sustaining neuroinflammatory processes [62]
• Macrophage-Mediated Feedback Loop: Single-cell analysis reveals that COVID-19 lung pro-inflammatory macrophages induce this cytokine triad, creating a self-sustaining feedback loop that persists beyond acute infection and contributes to Long COVID pathogenesis [62]

4.3.2 Neuroinflammatory Biomarkers in Long COVID

• Neurofilament Elevation: Serum neurofilament light chain levels remain elevated at 10 months post-infection (18.3 pg/mL vs 7.2 pg/mL in controls) in Long COVID patients with persistent symptoms, indicating ongoing neuro-axonal damage. While biomarker elevation at 1 week post-infection correlates significantly with cognitive impairment, this relationship becomes non-significant at 10 months follow-up, despite paradoxical worsening of self-reported cognitive symptoms. This temporal dissociation between objective biomarkers and subjective symptoms highlights the complex pathophysiology of Long COVID neurological manifestations [63]
• Tryptophan Catabolite Pathway Activation: Meta-analysis demonstrates significant activation of the tryptophan catabolite pathway in Long COVID, with large effect size increase in KYN/TRP ratio (SMD = 0.755), indicating robust IDO enzyme activation. This manifests as decreased tryptophan levels and increased kynurenine production, supporting the role of microglial-driven neuroinflammation in Long COVID pathogenesis. Notably, neurotoxic downstream metabolites were not significantly elevated, suggesting specific rather than generalized pathway hyperactivation [64]

4.4 Regional Neuroinflammatory Patterns Specific to Long COVID

4.4.1 CCL11-Mediated Hippocampal Dysfunction in Long COVID

• CSF and Plasma CCL11 Elevation: Mild respiratory COVID induces persistent elevation of CCL11 in cerebrospinal fluid, with levels increasing from 7 days to 7 weeks post-infection. In humans with long COVID, elevated plasma CCL11 levels specifically correlate with cognitive symptoms ("brain fog"), with demographic factors including sex and autoimmune disease history influencing levels. Systemic CCL11 administration recapitulates key pathological features: hippocampus-specific microglial reactivity and impaired neurogenesis, demonstrating direct mechanistic links between CCL11 and cognitive dysfunction in Long COVID. This study reveals striking similarities between Long COVID and cancer therapy-related cognitive impairment, including white-matter-selective microglial activation and oligodendrocyte loss [65]

4.4.2 Neuroplasticity Dysfunction in Long COVID

• Synaptic Plasticity Disruption: Neuroinflammation in Long COVID results from systemic inflammation that blunts monoamine neurotransmission, decreases trophic factors, and activates both astrocytes and microglia. This severely impacts both functional and structural plasticity, leading to cognitive sequelae [66]

* Disrupted neurotransmitter systems, particularly involving GABAergic and glutamatergic pathways which could arise from astrocytic dysfunction and impaired glutamate uptake capacity, contributing to excitotoxicity and neuroinflammation.  The glutamatergic dysregulation and a concomitant reduction in GABAergic inhibitory control may create a state of neural dysfunction and metabolic stress. [102]

• Neurotrophic Factor Depletion: Proposed mechanisms of microglial dysfunction in neuro-PASC include decreased brain-derived neurotrophic factor (BDNF) levels and NLRP3 inflammasome involvement, which may contribute to reduced long-term potentiation and altered neuroplasticity in post-COVID neurological sequelae [17]

4.5 Complement-Mediated Microglial Activation in Long COVID

4.5.1 TLR4-Mediated Cognitive Dysfunction

• SARS-CoV-2 Spike Protein Mechanism: SARS-CoV-2 spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice. Spike protein infusion induces microglial activation in the dentate gyrus, with C1q blockade preventing synaptic loss, suggesting complement-mediated cognitive dysfunction in Long COVID [67]

4.6 Microglial Resolution Pathway Dysfunction in Long COVID

4.6.1 Dysregulated Microglial Function

• Primed Microglial Dysfunction: Microglia can become dysfunctional with aging, chronic infection, or stress. These dysregulated microglia are hyperreactive to signals from the peripheral immune system, producing an exaggerated and prolonged central cytokine response to an otherwise mild immune challenge. The primed microglia then become resistant to normal regulation, failing to revert to the quiescent state after inflammation resolution. This model of dysregulated, activated, and primed brain cells and microglia, responding to peripheral or central cytokines, can explain the chronic and relapsing clinical course of many Long COVID symptoms [70]

4.6.2 Impaired Anti-Inflammatory Resolution in Long COVID

• Failed Resolution Mechanisms: Microglial cells in Long COVID fail to transition from activated pro-inflammatory states to anti-inflammatory, tissue-repair phenotypes. This resolution failure perpetuates chronic neuroinflammation and prevents restoration of normal brain homeostasis [66]

4.7 Molecular Mechanisms of COVID-19 Microglial Dysfunction

4.7.1 Transcriptional Reprogramming in COVID-19

• Gene Expression Alterations: COVID-19 patients demonstrate transcriptional signatures in brain tissue revealing dysregulation of brain and choroid plexus cell types, with microglial populations associated with pathological states observed in human neurodegenerative diseases [68]

4.7.2 Long COVID Neuroplasticity Dysfunction

• Synaptic Pruning Abnormalities: Long COVID is associated with reduced levels of BDNF, altered crosstalk between circulating immune cells and microglia, increased levels of inflammasomes, cytokines and chemokines, as well as alterations in signaling pathways that impact neural synaptic remodeling and plasticity. These mechanisms involve fractalkines, the complement system, the expression of SIRPα and CD47 molecules, and altered matrix remodeling [66]

4.8 Integration with Multi-System Long COVID Pathogenesis

4.8.1 Connection to Viral Antigen Persistence (Section 1)

• Persistent Antigen-Driven Activation: SARS-CoV-2 spike protein persistence in brain pericytes and neurons provides ongoing stimulus for microglial activation, with spike protein specifically detected in PDGFR+ pericytes in post-mortem COVID-19 brain tissue [3]

4.8.2 Blood-Brain Barrier Interface (Section 3)

• BBB-Microglial Feedback in Long COVID: BBB disruption in Long COVID enables peripheral inflammatory mediator infiltration that sustains microglial activation, while activated microglia release factors that further compromise BBB integrity, creating self-perpetuating neuroinflammatory cycles [10]

4.8.3 Vascular-Neuroinflammatory Coupling (Section 5)

● COVID-19 Perivascular Microglial Activation: Microglial nodules and activated microglia concentrate in perivascular spaces in COVID-19 brains, representing COVID-19-specific microanatomic immune niches with context-specific cellular interactions enriched for activated CD8+ T cells [69]

GO TO TOP OF PAGE

5: VASCULAR DYSFUNCTION AND MICROCLOT FORMATION

5.1 Cerebrovascular Endothelial Dysfunction in Long COVID

5.1.1 Persistent Cerebrovascular Reactivity Impairment

• Endothelial Activation Phases: Endothelial activation occurs through two distinct phases: Type I endothelial cell activation (initial stimulation) and Type II endothelial cell activation (sustained activation), representing progression from acute endothelial response to chronic pathological activation in Long COVID [19]
• Long-term Vascular Dysfunction: Neuroimaging studies using cerebrovascular reactivity mapping show significantly more abnormal CVR values in attention networks in Long COVID patients, with these abnormal values correlating with objective memory performance deficits [71]
• Cerebral Perfusion Deficits: Arterial spin labeling MRI demonstrates significantly reduced global cerebral blood flow in post-COVID-19 subjects with subjective cognitive complaints (median 37.7 [IQR 33.3–44.8] vs 44.6 [40.8–48.7] ml/100g/min in controls, p=0.011) with bilateral frontal, temporal, and parietal cortex involvement 2-10 months post-infection. However, none of the included subjects scored below the pathological threshold on cognitive testing, and no correlation was found between perfusion deficits and objective cognitive scores, limiting the clinical interpretation of these findings [72]

5.1.2 Spike Protein-Mediated Cerebral Endothelial Activation

• Direct Endothelial Cell Activation: In vitro studies demonstrate that SARS-CoV-2 spike protein S1 subunit directly activates human endothelial cells in culture, leading to dose-dependent increases in TNF, ICAM1, and VCAM1 expression via ACE2-dependent pathways. Proteomics analysis identified 216 ACE2-interacting proteins enriched for viral response and inflammation pathways, providing mechanistic insights into spike protein-mediated endothelial dysfunction. These findings are based on acute (24-hour) exposure to recombinant protein in cell culture and require validation in Long COVID patients with chronic spike protein exposure [73]
• Renin-Angiotensin System Disruption: SARS-CoV-2 utilizes ACE2 for endothelial cell entry, disrupting both renin-angiotensin-aldosterone system and renin-angiotensin system function. Endothelial cells exhibit activity for both systems, with their disruption contributing to vascular dysfunction [19]

5.1.3 von Willebrand Factor/ADAMTS-13 Axis Imbalance

• Sustained Endotheliopathy: Persistent elevation of von Willebrand factor and plasma Factor VIII with vWF/ADAMTS-13 axis imbalance characterizes Long COVID endothelial dysfunction. The imbalance contributes to enhanced platelet aggregation and microthrombotic processes affecting cerebral microcirculation [19]

5.1.4 Immune-Endothelial Cell Interactions in Long COVID

• Enhanced PBMC Adhesion: Peripheral blood mononuclear cells from long COVID patients demonstrate significantly increased adhesion to human brain endothelial cells in vitro compared to unaffected individuals, indicating heightened inflammatory cell-endothelial interactions that promote neuroinflammation [10]
• Serum-Mediated Endothelial Activation: Exposure of brain endothelial cells to serum from long COVID patients induces dose-dependent upregulation of inflammatory markers, with significant increases in TNF and VCAM1 expression compared to control serum, demonstrating circulating factors that perpetuate vascular dysfunction [10]
• Transcriptomic Evidence of Coagulation Dysregulation: Peripheral blood mononuclear cells from long COVID patients with brain fog demonstrate significant dysregulation of coagulation system pathways and dampened adaptive immune responses. This coagulation system dysregulation represents the most significantly altered pathway in brain fog patients, directly linking systemic vascular dysfunction to neurological manifestations [10]

5.2 Fibrinolysis-Resistant Microclot Formation in Long COVID

5.2.1 Amyloid-like Fibrin Network Formation

• Spike Protein-Fibrinogen Interactions: SARS-CoV-2 spike protein directly binds fibrinogen with high affinity (dissociation constant 390 nM), leading to formation of amyloid-like fibrin networks that resist normal breakdown mechanisms. Specific binding occurs between fibrinogen γ364–395 and spike NTD region, creating spike-fibrin complexes with marked resistance to plasmin-mediated fibrinolysis. These structurally abnormal fibrin clots exhibit heightened proinflammatory activity and drive systemic thromboinflammation in both acute COVID-19 and Long COVID [74]
• Microclot Composition and Size: Long COVID patients demonstrate formation of fibrinolysis-resistant microclots reaching 200 μm diameter through spike protein-fibrinogen-serum amyloid A interactions. Persistent microclots alter erythrocyte structure and may entrap other proteins, potentially contributing to microvascular dysfunction [79]. These microclots require double trypsinization and harsh chemical conditions for solubilization, explaining why standard coagulation tests appear normal while patients remain symptomatic [75]

5.2.2 Entrapped Inflammatory Molecules

• Protein Entrapment: Comprehensive proteomics analysis of 99 Long COVID patients reveals that fibrinolysis-resistant microclots entrap von Willebrand Factor (2.6-fold increase, p=9.4×10⁻¹¹), Platelet Factor 4 (3.5-fold increase, p=3.5×10⁻⁰⁵), α-2-antiplasmin (1.3-fold increase), and inflammatory proteins including galectin-3-binding protein (2.3-fold increase, p=3.9×10⁻⁰⁷) and thrombospondin-1 (2.4-fold increase, p=5.1×10⁻⁰⁵). These entrapped molecules perpetuate inflammatory responses and remain invisible to standard blood tests such as C-reactive protein, explaining why patients with severe symptoms (74% with constant fatigue, 71% with cognitive impairment) may have normal laboratory results at 221±99 days post-diagnosis [75]
• Failed Fibrinolysis Mechanisms: Persistent microclot pathology in Long COVID is characterized by substantially increased α-2-antiplasmin and serum amyloid A (SAA) trapped in fibrinolysis-resistant microclot deposits months post-infection. Using double trypsinization protocols, the study demonstrated that these anomalous amyloid deposits require harsh proteolytic conditions for solubilization, unlike normal plasma proteins from controls. The fibrinolysis resistance explains symptom persistence and indicates that conventional anticoagulation approaches may be insufficient [76]
• Suboptimal Fibrinolytic Response: Long COVID demonstrates suboptimal fibrinolytic response contributing to persistent clotting abnormalities and ongoing vascular dysfunction [19]

5.2.3 Platelet Hyperactivation

• Acute COVID-19 Platelet Dysfunction as Precedent: Severe acute COVID-19 demonstrates IgG-mediated procoagulant platelet formation through FcγRIIA-dependent pathways, with strong correlations to thrombotic events. Whether similar antibody-mediated platelet activation persists in Long COVID requires investigation [77]
• Antiphospholipid Antibody Enhancement: Formation of antiphospholipid antibodies in Long COVID enhances endothelial activation and coagulation pathway dysfunction, contributing to persistent thrombotic risk and microvascular compromise [19]

5.3 Cerebrovascular Consequences in Long COVID

5.3.1 Microvascular Occlusion and Neuronal Injury

• Neurological Impact of Large Microclots: Fibrinolysis-resistant microclots reaching 200 μm diameter have the theoretical potential to cause microvascular occlusion that could contribute to neuronal injury. The size of these microclots suggests they may be capable of impacting cerebral microcirculation [11]
• Comprehensive Vascular Pathology: Endothelial pathology encompasses barrier impairment, compromised vasodilation, increased vessel rigidity, aberrant blood flow, and thrombotic phenomena. Endothelial pathology within microvessels leads to comprehensive vascular dysfunction and capillary rarefication [19]
• VEGF-A Imbalance: Elevated VEGF-A levels create imbalances in angiogenesis and nociception pathways, leading to microvascular and neurological damage that explains clinical manifestations and ongoing vasculopathy in Long COVID [19]

5.3.2 Blood-Brain Barrier Compromise

• Vascular-Mediated BBB Dysfunction: Persistent vascular dysfunction contributes to sustained blood-brain barrier disruption, with dynamic contrast-enhanced MRI demonstrating significantly increased whole-brain leakage in Long COVID patients with brain fog up to 7 months post-infection, particularly in temporal and frontal regions [10]
• Quantified Vascular-Structural Relationships: BBB permeability demonstrates significant negative correlations with global brain volume (r=-0.614, p=0.0004), right cerebrum volume (r=-0.544, p=0.002), and left cerebrum volume (r=-0.557, p=0.002), while showing positive correlation with CSF volume (r=0.595, p=0.0007). These correlations establish direct quantitative relationships between vascular dysfunction and structural brain changes in long COVID [10]

For detailed blood-brain barrier mechanisms, see Section 3

5.3.3 TGF-β as Brain Fog-Specific Vascular Mediator

• TGF-β Elevation and Correlation: Transforming growth factor-β emerges as a specific biomarker elevated uniquely in long COVID patients with brain fog compared to those without neurological symptoms. TGF-β levels correlate significantly with BBB dysfunction percentage, CSF volume increase, and structural brain changes including brainstem and amygdala volume alterations, establishing TGF-β as a key mediator linking vascular dysfunction to neurological symptomatology [10]

5.4 Integration with Long COVID Pathogenesis

5.4.1 Connection to Viral Antigen Persistence (Section 1)

• Persistent Spike Protein Effects: Continued presence of spike protein in tissues provides ongoing stimulus for endothelial activation and microclot formation, perpetuating vascular dysfunction months post-infection [3]

For detailed viral persistence mechanisms, see Section 1

5.4.2 Neuroinflammatory Coupling (Section 4)

• Vascular-Neuroinflammatory Feedback: Endothelial dysfunction and microclot formation create conditions that facilitate neuroinflammatory responses, while activated microglia release factors that further compromise endothelial integrity, creating self-perpetuating pathological cycles [10]

For detailed neuroinflammatory mechanisms, see Section 4

5.4.3 Complement-Mediated Vascular Injury (Section 2)

Persistent Complement Dysregulation:

• Complement System Activation: Long COVID patients demonstrate persistent complement dysregulation with signs of thromboinflammation at 6 months post-infection, with analysis of >6500 proteins in 268 longitudinal samples revealing dysregulated activation of the complement system in individuals experiencing Long COVID [78]
• Alternative and Classical Pathway Activation: Active Long COVID is characterized by terminal complement system dysregulation and ongoing activation of the alternative and classical complement pathways, the latter associated with increased antibody titers against several herpesviruses possibly stimulating this pathway [78]

Complement-Mediated Cellular Damage:

• Tissue Injury and Thromboinflammation: Long COVID patients showed elevated tissue injury markers in blood and a thromboinflammatory signature, characterized by markers of endothelial activation, such as von Willebrand factor, and red blood cell lysis [78]
• Terminal Complement Complex Imbalance: Long COVID patients showed imbalanced terminal complement complex (TCC) formation, marked by increased soluble C5bC6 complexes and decreased levels of C7-containing TCC formations. This suggests increased membrane insertion of TCCs in Long COVID patients, contributing to tissue damage [78]

Thromboinflammatory Signature:

• Hemolysis and Platelet Activation: Markers of hemolysis, tissue injury, platelet activation, and monocyte-platelet aggregates were increased in Long COVID. Long COVID patients had elevated platelet activation markers and monocyte-platelet aggregates at 6-month follow-up, particularly in cases where Long COVID persisted for 12 months or more [78]

For comprehensive complement system activation, see Section 2

GO TO TOP OF PAGE

6: WHITE MATTER MICROSTRUCTURAL ALTERATIONS

Cerebral white matter is crucial for brain function because it forms the information superhighways of the brain, using myelinated axons to rapidly transmit signals between different gray matter areas, enabling complex cognitive abilities like learning, memory, language, and reasoning  

6.1 Advanced Neuroimaging Methods for White Matter Assessment

6.1.1 Methodological Advances in Diffusion Imaging

• NODDI Superior Sensitivity: Neurite orientation dispersion and density imaging (NODDI) demonstrates superior sensitivity for detecting subtle white matter microstructural changes compared to conventional diffusion tensor imaging (DTI) metrics. NODDI provides direct measurement of biologically relevant parameters in three microstructural environments: intracellular, extracellular, and free water compartments, enabling more precise characterization of white matter pathology [20]

6.1.2 Advanced Diffusion Imaging Approaches in Long COVID

Diffusion Kurtosis Imaging Superior Sensitivity:

• DKI Methodological Advantage: A prospective study of 22 recovered COVID-19 patients at approximately 1 year post-infection (mean follow-up 10-14 months) compared to 16 healthy controls demonstrates that DKI metrics show superior sensitivity for detecting white matter microstructural changes. Importantly, 13 of 31 patients (41.9%) continued to exhibit neurological symptoms at this timeframe, including fatigue (59.09%), insomnia (40.91%), headache (18.18%), and visual disturbances (4.55%). While DKI metrics (mean kurtosis [MK] and radial kurtosis [RK]) demonstrated significant reductions in specific brain regions (p < 0.05), DTI metrics (fractional anisotropy, mean diffusivity, radial diffusivity, and axial diffusivity) and NODDI metrics (neurite density index and orientation dispersion index) showed no significant differences between groups [80]
• Mean Kurtosis Reductions: DKI analysis revealed that recovered COVID-19 patients exhibited significant reductions in MK within the right inferior fronto-occipital fasciculus (IFOF) (cluster size: 14,793 voxels, p = 0.02), bilateral corticospinal tract, left IFOF, left inferior and superior longitudinal fasciculus, and left anterior thalamic radiation. The most significant reduction in MK was observed in the right IFOF, followed by the left corticospinal tract (cluster size: 1,964 voxels, p = 0.041) [80]
• Radial Kurtosis Changes: Significant reductions in RK were observed in the right IFOF (cluster size: 12,594 voxels, p = 0.017), left inferior longitudinal fasciculus (cluster size: 4,152 voxels, p = 0.038), left anterior thalamic radiation, and left corticospinal tract in recovered COVID-19 patients compared with controls [80]

Mechanistic Interpretation of DKI Findings:

• Microstructural Complexity Loss: Mean kurtosis reflects the heterogeneity and complexity of brain microstructure, with reductions indicating loss of cellular structures including white matter volume, myelinated fiber volume, and axonal integrity. Radial kurtosis is highly sensitive to axon and myelin integrity, with reductions indicating weakened restriction of water molecule diffusion, suggesting neuronal and myelin damage in corresponding brain regions [80]

Generalized Diffusion Encoding:

• QTI Widespread Damage Detection: Advanced diffusion MRI with generalized diffusion encoding reveals widespread white matter damage in patients previously hospitalized for COVID-19 with persisting symptoms at 7-month follow-up. Using Q-space trajectory imaging (QTI) with generalized time-varying magnetic field gradients, significant differences were detected in all QTI-derived metrics across white matter regions. Fractional anisotropy, microscopic anisotropy, and orientational coherence were significantly lower in patients, while mean diffusivity, axial diffusivity, radial diffusivity, and variance in compartment size were significantly higher. These widespread alterations indicate vasogenic edema, demyelination, and axonal damage, with microscopic anisotropy changes suggesting primarily loss of local anisotropy rather than white matter fiber coherence disruption [81]

6.2 Regional White Matter Pathology in Long COVID

6.2.1 Corpus Callosum Microstructural Alterations

Tract-Specific Vulnerability:

• Interhemispheric Connectivity Impact: Corpus callosum demonstrates particular vulnerability in Long COVID patients, with microstructural alterations affecting interhemispheric connectivity. The corpus callosum serves as a critical commissural pathway connecting bilateral cerebral hemispheres making it susceptible to inflammatory and hypoxic insults [82]

6.2.2 Association Fiber Involvement

Superior Longitudinal Fasciculus Changes:

• Long Association Tract Damage: Superior longitudinal fasciculus pathways demonstrate microstructural abnormalities in recovered COVID-19 patients at approximately 1 year post-infection, as evidenced by reduced mean kurtosis values. These long association fiber tracts connect frontal, parietal, and temporal cortical regions [80]

Inferior Fronto-Occipital Fasciculus Alterations:

• Most Significant White Matter Pathology: Right inferior fronto-occipital fasciculus shows the most significant reductions in both mean kurtosis and radial kurtosis values in recovered COVID-19 patients compared to controls, indicating decreased structural complexity. This tract connects frontal executive areas with occipital visual processing regions. The right IFOF demonstrated the largest affected volume (14,793 voxels for MK reduction, 12,594 voxels for RK reduction), representing the most prominent white matter pathology in recovered COVID-19 patients [80]

6.2.3 Projection Pathway Changes

Corticospinal Tract Involvement:

• Motor Pathway Alterations: Bilateral corticospinal tract demonstrates significant microstructural alterations in recovered COVID-19 patients at approximately 1 year post-infection, with the left corticospinal tract showing the second-largest affected volume (1,964 voxels) for mean kurtosis reduction. These projection pathways are critical for motor control [80]

Corona Radiata Involvement:

• Cortico-Cortical Connectivity Disruption: Corona radiata pathways demonstrate microstructural alterations that may contribute to motor control and cognitive processing deficits through disrupted corticospinal and corticocortical connectivity in Long COVID patients with persistent neurological symptoms [81]

6.3 Oligodendrocyte Dysfunction and Myelin Pathology

6.3.1 Cellular Mechanisms from Preclinical Models

Quantitative Oligodendrocyte Loss:

• Distributed Myelin Loss Pattern: Following mild respiratory COVID-19 in mice, decreased oligodendrocytes and myelin loss were evident in subcortical white matter for at least 7 weeks post-infection. Loss of myelinated axons was distributed throughout white matter rather than in focal, plaque-like areas as would be expected for multiple sclerosis-like demyelination [82]
• Oligodendrocyte Subtype Depletion: Both oligodendrocyte precursor cells (PDGFRα+) and mature oligodendrocytes (ASPA+, CC1+) showed significant reduction in the cingulum of the corpus callosum at 7 days and 7 weeks post-infection [82]

Temporal Progression of Oligodendrocyte Pathology:

• Biphasic Oligodendrocyte Loss: The temporal dynamics of white matter pathology demonstrate distinct phases: oligodendrocyte precursor cells (PDGFRα+) show maintenance at 7 days post-infection with mild decrease by 7 weeks, while mature oligodendrocytes (ASPA+, CC1+) demonstrate immediate and substantial depletion (approximately one-third reduction) evident at 7 days that persists throughout the 7-week observation period [82]

Ultrastructural Myelin Characteristics:

• Frank Myelin Loss: Transmission electron microscopy revealed frank loss of myelin with decreased myelinated axon density in subcortical white matter evident by 7 days post-infection. Changes in myelin sheath thickness relative to axon diameter (g-ratio) were not conclusively identified in the remaining myelin sheaths after mild respiratory COVID, in contrast to methotrexate chemotherapy exposure. The pattern of myelin loss was distributed throughout white matter rather than focal or plaque-like, distinguishing this pathology from inflammatory demyelinating disorders such as multiple sclerosis [82]

6.3.2 CCL11-Mediated White Matter Pathology

Mechanistic Pathways:

• CSF CCL11 and White Matter Damage: Elevated cerebrospinal fluid CCL11 levels, which increased significantly from 7 days to 7 weeks post-infection, were specifically associated with white matter pathology. Systemic CCL11 administration recapitulated key pathological features including hippocampus-selective microglial reactivity and impaired neurogenesis, providing direct mechanistic links between peripheral inflammation and central white matter dysfunction [82]

Human Clinical Correlations:

• Plasma CCL11 and Cognitive Symptoms: Humans with lasting cognitive symptoms post-COVID exhibit elevated plasma CCL11 levels compared to those with long COVID lacking cognitive symptoms. Multiple linear regression analysis identified patient sex and history of autoimmune disease as significant variables accounting for CCL11 variability, with male patients and those with autoimmune disease history showing significantly higher CCL11 levels [82]

6.3.3 White Matter-Selective Microglial Reactivity

Microglial Activation Pattern:

• Selective White Matter Targeting: White-matter-selective microglial reactivity was found in both mice and humans following COVID-19, with persistent microglial activation in subcortical and hippocampal white matter regions but not in gray matter [82]
• Downstream Pathological Consequences: This microglial reactivity was associated with downstream consequences including reduced adult neurogenesis and loss of oligodendrocytes and myelinated axons, resembling patterns observed in cancer-therapy-related cognitive impairment [82]

Neurotoxic Astrocyte Involvement:

• Microglial-Astrocyte-Oligodendrocyte Cascade: Reactive microglia can indirectly affect oligodendrocytes by inciting neurotoxic astrocyte reactivity that kills oligodendrocytes through toxic lipid secretion. This establishes direct pathogenic links between persistent neuroinflammation and white matter structural damage, creating a mechanistic cascade from microglial activation to oligodendrocyte death [82]

6.4 Clinical Correlations in Long COVID White Matter Pathology

6.4.1 Symptom-Specific White Matter Changes

Cognitive-Structural Correlations:

• Direct Symptom Correlation: Cerebral microstructural alterations in Post-COVID-condition are directly related to cognitive impairment, olfactory dysfunction, and fatigue, revealing widespread alterations in cerebral microstructure attributed to a shift in volume from neuronal compartments to free fluid. These findings establish direct correlations between white matter pathology and Long COVID symptomatology [22]

6.4.2 Functional Network Consequences

Network-Based Hypo-connectivity:

• Widespread Connectivity Reduction: Widespread functional connectivity reduction across 7 of 8 functional networks, with 82% of affected connections involving the default mode network. These connectivity disruptions directly correlate with white matter microstructural alterations in Long COVID patients [23]

Processing Efficiency Impairment:

• Information Flow Disruption: Reduced local efficiency in fatigue-related brain nodes with altered effective connectivity patterns disrupting information flow, demonstrating the functional consequences of white matter structural damage in Long COVID [23]

6.5 Neurofilament Biomarkers of Axonal Damage

6.5.1 Longitudinal Elevation of Neuronal and Glial Biomarkers

Clinical Study Population:

• Worker Cohort Analysis: A cohort study of 147 adult workers with previous asymptomatic SARS-CoV-2 infection (36%) or mild COVID-19 (64%) assessed one week (T0) and ten months (T1) after test negativization, compared to 82 age and BMI-matched healthy controls. Mild COVID-19 was defined as presenting any COVID-19 symptoms without shortness of breath, dyspnoea, or abnormal chest images, while asymptomatic infection was confirmed by positive SARS-CoV-2 test without COVID-19 symptoms [83]

Initial Assessment Findings:

• Early Biomarker Elevation: At one week post-negativization (T0), both serum neurofilament light chain (median 22.83 pg/mL vs 7.21 pg/mL in controls) and glial fibrillary acidic protein (median 146.32 pg/mL vs 63.53 pg/mL in controls) levels were significantly elevated in COVID-19 patients compared to healthy controls (p < 0.001 for both), indicating ongoing neuro-axonal damage and astrocytic activation [83]

Cognitive Impairment Correlations:

• Biomarker-Cognition Association: COVID-19 patients with cognitive impairment (CFQ score >43) demonstrated significantly higher biomarker levels at T0: sNfL (median 45.03 pg/mL vs 22.42 pg/mL) and sGFAP (median 194.15 pg/mL vs 131.28 pg/mL) compared to those without cognitive impairment (p = 0.005 for both), establishing direct associations between CNS damage biomarkers and cognitive dysfunction [83]

6.5.2 Temporal Dissociation Between Biomarkers and Symptoms

Ten-Month Follow-up Findings:

• Persistent but Reduced Elevation: At ten months post-infection (T1), 49 workers with persistent symptoms showed significant biomarker reduction compared to baseline (median sNfL 18.3 pg/mL, median sGFAP 77.2 pg/mL), yet levels remained significantly elevated compared to healthy controls (median sNfL 7.2 pg/mL, median sGFAP 63.5 pg/mL), suggesting ongoing neuronal and astrocytic damage despite symptom resolution in some patients [83]

Paradoxical Clinical-Biomarker Relationship:

• Temporal Dissociation Pattern: A striking temporal dissociation emerged at ten months: while biomarker levels decreased, self-reported cognitive impairment scores significantly worsened (mean CFQ scores increased from 18.1 to 27.1, p < 0.01). At T1, 14.3% of patients had CFQ scores >43, but sNfL and sGFAP levels no longer differed significantly between cognitively impaired and non-impaired groups. This paradoxical relationship suggests that early neuronal and glial damage may resolve while subjective cognitive impairment persists or becomes more pronounced [83]

6.6 Temporal Progression and Recovery Patterns

6.6.1 Dynamic Recovery Trajectories

Longitudinal Analysis:

• Gradual Recovery with Persistent Abnormalities: Among diffusion parameters, volume fraction of the isotropic diffusion compartment (Viso) showed statistical significance after correction for multiple comparisons at two years, indicating gradual recovery but persistent subtle abnormalities in some recovered COVID-19 patients [21]

6.6.2 Structure-Function Correlations

White Matter as Functional Biomarker:

• Cognitive Function Correlation: White matter microstructure serves as a biomarker of cognitive function in recovered COVID-19 patients with persistent neurological changes. Direct correlation analysis demonstrates that greater white matter abnormalities at 2-year follow-up associated with more severe cognitive deficits, establishing the functional significance of structural alterations [21]

6.7 Mechanistic Integration with Other Pathogenic Mechanisms

6.7.1 Connection to Neuroinflammation (Section 4)

Microglial-White Matter Interface:

• Direct Oligodendrocyte Targeting: White matter microglial reactivity creates conditions that directly impact oligodendrocyte survival and myelin integrity. Reactive microglia can indirectly affect oligodendrocytes by inciting neurotoxic astrocyte reactivity that kills oligodendrocytes through toxic lipid secretion, establishing direct pathogenic links between persistent neuroinflammation and white matter structural damage [82]
• CCL11-Mediated Pathway: CCL11-mediated neuroinflammation specifically targets white matter regions, creating a mechanistic pathway from systemic inflammation to focal white matter pathology in Long COVID patients with cognitive symptoms [82]

Chemotherapy Pathology Comparison:

• Shared Pathophysiological Mechanisms: The oligodendrocyte loss observed in Long COVID demonstrates similar magnitude to that seen in methotrexate chemotherapy models at both 4 weeks and 6 months post-treatment. This parallel pathology suggests shared pathophysiological mechanisms between COVID-related and chemotherapy-related cognitive impairment, supporting potential therapeutic approaches derived from cancer-therapy-related cognitive impairment research [82]

For comprehensive neuroinflammation and microglial activation mechanisms, see Section 4

6.7.2 Blood-Brain Barrier Interface (Section 3)

• Vulnerability to BBB Disruption: White matter regions demonstrate particular vulnerability to BBB disruption effects due to relatively sparse vascular architecture compared to gray matter regions. The persistence of BBB dysfunction with sustained inflammatory mediator infiltration contributes to ongoing white matter inflammatory changes and oligodendrocyte dysfunction in Long COVID patients with brain fog [10]

For detailed blood-brain barrier disruption mechanisms, see Section 3

6.7.3 Vascular Dysfunction Contributions (Section 5)

• Perfusion-Dependent White Matter Changes: Chronic hypoperfusion and microclot formation particularly impact white matter regions due to their dependence on adequate perfusion for metabolically active oligodendrocytes and myelin maintenance processes. The formation of fibrinolysis-resistant microclots reaching 200 μm diameter may compromise white matter microcirculation, contributing to the observed oligodendrocyte loss and myelin pathology [75]

For comprehensive vascular dysfunction and microclot formation mechanisms, see Section 5

6.7.4 Spike Protein-Mediated White Matter Damage (Section 1)

Direct Oligodendrocyte Effects:

• Pericyte-Oligodendrocyte Interface: Post-mortem analysis demonstrates SARS-CoV-2 spike protein colocalization with PDGFR+ pericytes in brain tissue, establishing direct anatomical proximity to the oligodendrocyte-myelin unit. This spatial relationship, combined with the persistent detection of spike protein in brain pericytes months post-infection, suggests potential direct effects on oligodendrocyte survival and myelin maintenance processes. The distribution of spike protein in brain pericytes and proximity to white matter regions provides a mechanistic basis for the observed white matter pathology in Long COVID patients [3]

For detailed viral persistence mechanisms, see Section 1

6.7.5  Clinical Implications of White Matter Damage 

Cognitive Impairment 

Correlations between cognitive status and brain abnormalities reveal a relationship between altered connectivity of white matter regions and impairments of episodic memory, overall cognitive function, attention and verbal fluency. (Serrano Del Pueblo V 2024) 

Demyelinating Syndromes

There have been reported cases of new or worsening multiple sclerosis and or other demyelinating diseases after a COVID infection and after a COVID vaccine.     

Ismaila et al. reported 32 cases of CNS demyelination following all types of approved COVID-19 vaccines. Voysey et al reported three cases of Acute Transverse Myelitis; one was diagnosed with idiopathic demyelination, and the other two patients had pre-existing MS.   Multiple case reports link the COVID vaccine to Optic Neuritis and other demyelinating syndromes like MOGAD, NMO and ADEM.  (Ismail II 2022) (Voysey M 2021) (Mele A 2022) (Nakano H 2022) (Khavet-Khoei 2021) (Garcia Dominquea 2024) (Hamed V 2024) (Moretti G 2024) (Elnahry L 2022) (Garnert JA 2022) (Havla, J 2022) (Jarius, S 2021) (Khayat-Khoei 2022) (Allugmani M 2023) (Rinaldi V 2022) (Tagliaferri A 2021) (Maniscalco GT 2021) (Mumoli, L 2021) (Simone, AM 2021) (Salunke M 2022) (Khayat-Khoel M  2022) (Ravindr G 2022) (Keika M 2022) (Roy, M 2022) (Czarnowsks A 2023) (Lim E 2023) (Guarnaccia J 2022) (Satoshi M 2021) (Do K 2023)

[References 158-184]

GO TO TOP OF PAGE

7: IMMUNE-MEDIATED METABOLIC DYSFUNCTION

7.1 Galectin-9 as Diagnostic and Functional Biomarker

7.1.1 Cognitive Dysfunction Biomarker Performance

• Diagnostic Accuracy: Plasma galectin-9 levels >1725 pg/ml distinguish long COVID patients with myalgic encephalomyelitis/chronic fatigue syndrome from healthy controls with 97% sensitivity and 100% specificity, establishing galectin-9 as a highly reliable diagnostic biomarker for Long COVID-associated cognitive dysfunction [24]
• Validation Across Cohorts: Diagnostic accuracy was confirmed in a validation cohort of 34 Long COVID patients, where a cut-off value >1702 pg/ml differentiated Long COVID from recovered individuals with 82.35% sensitivity and 95% specificity. This validation occurred across different SARS-CoV-2 variants (original Wuhan strain vs Delta/Omicron variants), demonstrating robust biomarker performance [24]
• Direct Cognitive Impairment Correlation: Galectin-9 levels demonstrate positive correlation with cognitive failure scores in Long COVID patients with ME/CFS (r=0.71, p<0.001), indicating that elevated galectin-9 levels directly associate with worse cognitive function and brain fog severity [24]   

*Galectin-9 (Gal-9), one of the most abundant beta-galactosidase-binding proteins secreted by active microglia, is elevated in brain tissue and cerebrospinal fluid in patients with AD, associating with cognitive impairments. Gal-9 binds to toll-like receptor 4 (TLR4) on microglia and activates the NLR family, pyrin domain containing 3 (NLRP3) inflammasome, promoting the secretion of interleukin-1β (IL-1β) and IL-18, which are toxic to neurons. (Guo X)

7.1.2 Inflammatory Network Integration

• Multi-Biomarker Correlations: Galectin-9 demonstrates significant positive correlations with multiple inflammatory markers including serum amyloid A (SAA) (r=0.68, p<0.01), IP-10 (r=0.65, p<0.01), soluble CD14 (sCD14) (r=0.62, p<0.01), and intestinal fatty acid-binding protein (I-FABP) (r=0.58, p<0.05), indicating systemic immune activation and gut-brain axis disruption [24]
• Cellular Source and Receptor Interactions: Activated innate immune cells, particularly neutrophils and monocytes, serve as primary sources of galectin-9 shedding, as evidenced by positive correlations with sCD14 levels. Galectin-9 interacts with multiple receptors including TIM-3, PD-1, CD44, CD45, and CD3, with biological consequences varying significantly depending on target cell type, receptor expression levels, and microenvironment [24]
• Functional Diversity: While galectin-9 interactions with TIM-3 and PD-1 promote CD8+ T cell exhaustion, galectin-9:CD3 interactions enhance TCR signaling in T cells. Similarly, galectin-9:CD44 interactions promote NK cell effector functions under physiological conditions but impair cytotoxic capabilities in chronic inflammatory states [24]
• Mechanistic Role in Neuroinflammation: Galectin-9 functions as a damage-associated molecular pattern that activates microglia and promotes neuroinflammatory responses. Elevated galectin-9 levels contribute to sustained microglial activation and chronic neuroinflammation observed in Long COVID patients with persistent cognitive symptoms [24]

7.2 Tryptophan-Kynurenine Pathway Dysregulation

7.2.1 Meta-Analytic Evidence of Pathway Activation

• Large-Scale Systematic Analysis: Meta-analysis of 14 studies comprising 1,167 participants (480 Long COVID patients, 687 controls) demonstrates significant activation of the tryptophan catabolite pathway. The kynurenine/tryptophan ratio shows large effect size elevation (standardized mean difference = 0.755; 95% CI: 0.119-1.392) in Long COVID patients compared to controls, indicating robust IDO enzyme activation [84]
• Pathway Specificity: Individual metabolite analysis reveals significant decreases in tryptophan levels (standardized mean difference = -0.520, CI: -0.793; -0.246) and increases in kynurenine concentrations after imputing missing studies (standardized mean difference = 1.176, CI: 0.474; 1.877) in Long COVID patients. Notably, downstream neurotoxic metabolite ratios including kynurenic acid/kynurenine and 3-hydroxykynurenine/kynurenine ratios were not significantly elevated, suggesting specific IDO activation rather than generalized pathway hyperactivation [84]

7.2.2 Neurobiological Consequences of IDO Activation

• IDO Enzyme Activation: The significantly elevated KYN/TRP ratio indicates robust activation of indoleamine 2,3-dioxygenase (IDO), the rate-limiting enzyme converting tryptophan to kynurenine. This IDO hyperactivation results in significant reduction of tryptophan availability for serotonin and melatonin synthesis while increasing kynurenine metabolites, creating conditions conducive to neuroinflammation and cognitive dysfunction [84]
• Immune-Metabolic Interface: Activated immune-inflammatory responses and increased oxidative stress in Long COVID induce IDO, the rate-limiting enzyme in tryptophan catabolism. This creates a pathogenic cycle where neuroinflammation drives metabolic dysfunction, which in turn perpetuates neuroinflammatory processes through altered neurotransmitter metabolism [84]

7.2.3 Clinical Implications of Pathway Dysregulation

• Therapeutic Target Identification: The consistent elevation of KYN/TRP ratios across multiple studies establishes the tryptophan-kynurenine pathway as a potential therapeutic target for Long COVID neurological manifestations. The specificity of IDO activation without generalized downstream metabolite elevation suggests targeted interventions may be effective [84]

7.3 Gut-Brain Axis Dysfunction

7.3.1 Intestinal Barrier Compromise

• Multi-Biomarker Evidence: Long COVID patients demonstrate elevated levels of intestinal permeability markers including LPS-binding protein, intestinal fatty acid-binding protein (I-FABP), and soluble CD14 (sCD14), indicating compromised gastrointestinal barrier integrity and subsequent microbial translocation. These markers correlate with systemic inflammation and cognitive dysfunction severity [24]
• Microbial Translocation Consequences: Compromised intestinal barrier function allows bacterial lipopolysaccharides and other microbial products to enter systemic circulation, triggering sustained inflammatory responses that contribute to neuroinflammation and cognitive impairment through the gut-brain axis [24]

7.3.2 Microbiome Dysbiosis Patterns

• ACE2-Dependent Dysbiosis Mechanism: SARS-CoV-2 induces dysbiosis via binding to and downregulating ACE2 receptors in gut epithelium, which also downregulates the tightly linked B0AT1 organic anion transporter, a known key modulator of gut microbiome composition [11]
• Specific Microbial Alterations: Depletion of commensal bacteria including Bacteroidaceae, Lachnospiraceae, and Ruminococcaceae families with concurrent expansion of opportunistic pathogens such as Enterococcus, Staphylococcus, Serratia, and Collinsella species. This dysbiotic shift reduces bacterial diversity and richness in Long COVID patients [11]
• SCFA-Producing Bacteria Depletion: Significant reduction in short-chain fatty acid-producing genera including Agathobacter spp., Fusicatenibacter spp., Roseburia spp., and Ruminococcaceae compared to healthy controls. This depletion reduces beneficial microbial metabolites that normally support gut barrier integrity and provide neuroprotective effects through vagal nerve and systemic circulation pathways [11]
• Inflammatory Microbiome Profile: Dysbiosis-associated microbial patterns activate M1 pro-inflammatory macrophages in intestinal mucosa, leading to release of TNF-α, IL-1β, and other inflammatory mediators. These cytokines enter systemic circulation and contribute to neuroinflammation through multiple pathways including vagal nerve signaling and blood-brain barrier compromise [11]

7.3.3 Gut-Brain Immune Communication

• Vagal Nerve Inflammatory Signaling: Intestinal inflammation secondary to barrier compromise and dysbiosis activates afferent vagal pathways that transmit inflammatory signals directly to brainstem nuclei. This neuroinflammatory signaling contributes to fatigue, cognitive dysfunction, and autonomic symptoms characteristic of Long COVID [11]
• Systemic Inflammatory Spillover: Gut barrier dysfunction enables translocation of inflammatory mediators from the intestinal compartment into systemic circulation, where they can access the brain through compromised blood-brain barrier regions and contribute to sustained neuroinflammation [11]

7.3.4 Experimental Validation of Gut-Brain Axis Dysfunction

• Koch's Postulates Fulfillment: Fecal microbiota transfer from Long COVID patients to germ-free mouse models successfully replicated cognitive dysfunction symptoms resembling Long COVID, providing direct causal evidence for gut microbiome involvement in neurological manifestations. Animals displayed compromised immune responses and demonstrated dysbiosis-induced memory impairment similar to that found in Long COVID patients. This represents the first experimental model demonstrating that downstream microbial alterations alone can reproduce Long COVID cognitive symptoms [11]

7.4 Integration with Multi-System Long COVID Pathogenesis

7.4.1 Connection to Immune Dysregulation (Section 2)

• Galectin-9-Mediated Immune Activation: Elevated galectin-9 functions as both a biomarker and active mediator of immune dysregulation, contributing to T cell exhaustion and sustained inflammatory responses characteristic of Long COVID. The strong correlations between galectin-9 and other inflammatory markers establish galectin-9 as a central node in the immune-metabolic dysfunction network [24]

For comprehensive immune system dysregulation mechanisms, see Section 2

7.4.2 Blood-Brain Barrier Interface (Section 3)

• Metabolic-Barrier Dysfunction Coupling: Gut barrier compromise and systemic inflammation contribute to blood-brain barrier disruption through shared inflammatory pathways. The correlation between intestinal permeability markers (I-FABP, sCD14) and neurological symptoms establishes direct links between gut-brain axis dysfunction and cerebral barrier compromise [24]

For detailed blood-brain barrier disruption mechanisms, see Section 3

7.4.3 Neuroinflammatory Amplification (Section 4)

• Tryptophan-Kynurenine Neuroinflammation: IDO activation and altered tryptophan metabolism directly contribute to sustained microglial activation and neuroinflammatory responses. The depletion of neuroprotective tryptophan derivatives combined with increased neuroactive kynurenine metabolites creates conditions that perpetuate neuroinflammation and cognitive dysfunction [84]
• Galectin-9 Microglial Activation: Elevated galectin-9 levels directly activate microglia and promote neuroinflammatory responses, contributing to the sustained microglial activation observed in Long COVID patients with persistent cognitive symptoms [24]

For comprehensive neuroinflammation and microglial activation mechanisms, see Section 4

7.4.4 Systemic Inflammatory Network (Section 2)

● Multi-Biomarker Inflammatory Profile: The correlation network including galectin-9, SAA, IP-10, sCD14, and I-FABP demonstrates integrated immune-metabolic dysfunction spanning multiple organ systems. This systemic inflammatory profile connects gut dysfunction, immune activation, and neurological symptoms through shared pathogenic pathways [24]

GO TO TOP OF PAGE

8: MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS

8.1 Structural and Functional Mitochondrial Damage

8.1.1 Ultrastructural Abnormalities and Novel Biomarkers

• Transmission Electron Microscopy Findings: Transmission electron microscopy of nasal mucosal and bronchial biopsy samples from Long COVID patients (n=5) compared to controls (n=5) revealed distinct mitochondrial structural abnormalities, notably including significant swelling, disrupted cristae, and an overall irregular morphology, which collectively indicate severe mitochondrial distress [25]
• Novel Mitochondrial Biomarkers: Analysis demonstrated increased levels of superoxide dismutase 1 (SOD1) signaling oxidative stress and elevated autophagy-related 4B cysteine peptidase (ATG4B) levels, indicating disruptions in mitophagy. Reduced levels of circulating cell-free mitochondrial DNA (ccf-mtDNA) in Long COVID patients serve as a novel biomarker for the condition [25]
• Mitochondrial Dynamics Disruption: Elevated levels of mitofusin 2 (MFN2) and dynamin-related protein 1 (DRP1) indicate disrupted balance between mitochondrial fusion and fission, while lactate dehydrogenase levels remained unchanged [25]
• Circulating ccf-mtDNA Analysis: Standardized qPCR methodology quantified five specific mitochondrial genes (MTATP6, MTCYTB, MTND1, MTND4, MTND5) in plasma samples from 32 Long COVID patients and 31 controls. Results revealed significant reduction in ccf-mtDNA content across all measured genes, with receiver operating characteristic curves demonstrating area under the curve values ranging from 0.715 to 0.758, suggesting moderate to high diagnostic accuracy [25]
• Mechanistic Interpretation: The reduction in circulating ccf-mtDNA levels suggests impaired mitochondrial recycling processes. This finding was contrary to initial hypothesis that increased mitophagy would elevate ccf-mtDNA levels, indicating that while mitochondrial clearance mechanisms are activated, they fail to completely remove damaged mitochondria [25]

8.2 Bioenergetic Dysfunction Assessment

8.2.1 Cellular Respiratory Function Analysis

• ATP Synthase Dysfunction: Long COVID patients demonstrate increased baseline oxygen consumption rates and ATP-linked respiration in peripheral blood mononuclear cells. These cells exhibit diminished capacity to maintain mitochondrial membrane potential when ATP synthase is inhibited with oligomycin, indicating bidirectional ATP synthase operation that dissipates energy as heat rather than producing usable ATP. Mitochondrial dysfunction correlates with autonomic dysfunction, reduced quality of life, and neurological symptom severity [85]
• Exercise-Induced Mitochondrial Failure: Controlled exercise studies using hyperoxic conditions to eliminate oxygen diffusion limitations reveal severely reduced mitochondrial capacity during physical activity. Succinate dehydrogenase activity was specifically reduced in Long COVID patients one day after exercise but not in healthy controls, indicating exercise-induced mitochondrial enzyme dysfunction correlating with post-exertional malaise timing [86]
• Post-Exertional Mitochondrial Enzyme Decline: While healthy controls maintain succinate dehydrogenase activity one day after maximal exercise, Long COVID patients show significant SDH reduction. This combination of reduced maximal mitochondrial respiration and decreased mitochondrial content contributes to post-exertional malaise pathophysiology. The temporal correlation between exercise-induced mitochondrial enzyme decline and cognitive symptom worsening provides mechanistic evidence for neurological manifestations [86]
• Glycolytic Recovery Impairment: Dihydroxyacetone phosphate, an intermediate in lipid biosynthesis and glycolysis, is reduced in Long COVID patient skeletal muscle following post-exertional malaise, indicating impaired metabolic recovery that fails to restore normal energy production pathways [86]

8.2.2 Magnetic Resonance Spectroscopy Biomarkers

• Phosphocreatine Recovery Dysfunction: ¹H and ³¹P MR spectroscopy demonstrates prolonged phosphocreatine recovery times (92.5 seconds vs 51.9 seconds in controls, p≤0.001) and reduced maximum oxidative flux by 0.16 mmol/L/s, providing objective biomarkers for mitochondrial ATP resynthesis capacity assessment [87]
• Brain Metabolic Alterations: Ultra-high-field 7T magnetic resonance spectroscopy reveals reduced total choline in the dorsal anterior cingulate cortex (p=0.0002) and significantly reduced total creatine levels compared to normal references, indicating membrane metabolism dysfunction and impaired phosphocreatine energy buffering systems critical for cognitive function [88]
• Systemic Creatine Depletion: Proton magnetic resonance spectroscopy at 1.5T demonstrates significantly reduced total creatine concentrations in skeletal muscle (vastus medialis) and multiple brain regions (thalamus, bilateral cerebral white and gray matter) compared to reference values. Lower creatine levels in skeletal muscle may correlate with severe muscle pain, indicating that creatine depletion represents a metabolic footprint of Long COVID [89]

8.2.3 Disease-Specific Metabolic Patterns

• Long COVID vs ME/CFS Distinction: Long COVID demonstrates unique neurometabolic patterns distinct from ME/CFS, with choline reduction in anterior cingulate cortex rather than lactate elevation seen in ME/CFS. This distinction supports different underlying pathophysiological mechanisms and reinforces that Long COVID neurological manifestations require specific therapeutic approaches [88]

8.3 Metabolic Biomarkers and Neurological Consequences

8.3.1 Comprehensive Metabolomic Profiling

• Multi-platform Mass Spectrometry Analysis: Analysis using CE-ESI(+/-)-TOF-MS, GC-Q-MS, and LC-ESI(+/-)-QTOF-MS identifies 447 lipid species with 46 relevant metabolites discriminating Long COVID from recovered patients, including decreased amino acid metabolism, reduced ceramide levels, and increased TCA cycle intermediates suggesting compensatory metabolic changes affecting neurological function [90]
• TCA Cycle Disruption: Long COVID patients demonstrate significantly lower concentrations of key tricarboxylic acid cycle metabolites including glutamate, FAD+, alpha-ketoglutarate, and citric acid in skeletal muscle at rest, with markedly reduced citric acid to lactate ratios indicating metabolic shift away from oxidative metabolism toward glycolytic pathways [86]
• Creatine-Phosphocreatine System Dysfunction: Skeletal muscle creatine concentrations are significantly lower in Long COVID patients, contributing to impaired energy buffering capacity essential for high-energy tissues including the brain. This creatine depletion reflects systemic energy metabolism dysfunction affecting both peripheral and central nervous system function [86]
• S-Adenosylmethionine Depletion: Long COVID patients demonstrate significantly lower S-adenosylmethionine concentrations in skeletal muscle, indicating reduced methylation capacity with neurological implications. SAM serves as the primary methyl donor for DNA methylation, neurotransmitter synthesis, and myelin maintenance, making its depletion relevant to cognitive dysfunction and brain fog [86]
• Purine Synthesis Impairment: Metabolites related to pyrimidine and purine synthesis, including ATP, are lower in Long COVID patients upon induction of post-exertional malaise. This metabolically demanding synthetic process is essential for cellular repair and neurotransmitter production, with impairment contributing to persistent neurological symptoms [86]
• Ceramide Metabolism Dysfunction: Significant reduction in ceramide plasma levels represents a key discriminating feature in Long COVID patients. Ceramides play crucial roles in neuronal membrane integrity and myelin maintenance, making their depletion particularly relevant to cognitive dysfunction and brain fog symptoms [90]

8.3.2 Long-term Metabolic Patterns

• Persistent Metabolic Alterations: Lactic acid, lactate/pyruvate, ornithine/citrulline, and arginine can distinguish long-COVID cases even two years post-infection. Long COVID causes mitochondrial dysfunction, redox state imbalance, impaired energy metabolism, and chronic immune dysregulation affecting neurological function [27]
• Magnetic Resonance Spectroscopy Evidence: Studies employing magnetic resonance spectroscopy observe alterations in muscle tissue and the brain indicative of mitochondrial dysfunction in long COVID sufferers, aligning with clinical reports of exercise intolerance and post-exertional malaise [28]

8.3.3 Neuroinflammatory Cascade Amplification

• ROS Storm: Mitochondrial oxidative stress ("ROS storm") with downstream immune dysregulation is consistent with elevated inflammatory signaling observed in long COVID [27]
• Mitochondrial ROS Production Markers: Long COVID patients demonstrate lower hydroxyphenyl acetic acid levels, typically associated with increased mitochondrial reactive oxygen species production. This biochemical signature indicates enhanced oxidative stress within mitochondria, contributing to progressive cellular damage in energy-demanding nervous system tissues [86]
• Self-Perpetuating Damage: Oxidative stress and chronic inflammation mutually reinforce each other, potentially contributing to long-term neurological dysfunction [29]
• DAMP Release: Cell death releases damage-associated molecular patterns, which activate additional inflammasomes, perpetuating neuroinflammation and contributing to persistent brain fog and cognitive symptoms [30]

8.4 Oxidative Stress and Antioxidant System Failure

8.4.1 Comprehensive Oxidative Damage Assessment

• OSTOX/ANTIOX Imbalance: Analysis of 120 Long COVID patients versus 36 controls demonstrates markedly elevated malondialdehyde (lipid peroxidation), protein carbonyls (protein oxidation), myeloperoxidase, and nitric oxide levels, with significantly reduced glutathione peroxidase and zinc antioxidant capacity. The OSTOX/ANTIOX ratio explains 60% of variance in neuropsychiatric symptoms [91]

8.5 Integration with Multi-System Long COVID Pathogenesis

8.5.1 Connection to Neuroinflammation (Section 4)

• Mitochondrial-Neuroinflammation Interface: TCA cycle metabolite depletion (glutamate, FAD+, alpha-ketoglutarate, citric acid) in Long COVID patients creates metabolic conditions promoting inflammatory responses. Reduced alpha-ketoglutarate availability impairs anti-inflammatory regulatory T cell function, while glutamate depletion affects neurotransmitter balance, facilitating sustained neuroinflammatory responses. Exercise-induced succinate dehydrogenase activity reduction provides an upstream metabolic trigger for neuroinflammatory cascades [86]

For comprehensive neuroinflammation and microglial activation mechanisms, see Section 4

8.5.2 Vascular Dysfunction Interface (Section 5)

• Metabolic-Vascular Integration: Persistent mitochondrial oxidative stress ("ROS storm") in long COVID generates systemic redox imbalance and immune dysregulation. These processes are well recognized contributors to endothelial dysfunction and vascular injury, suggesting that mitochondrial distress may indirectly exacerbate the vascular abnormalities observed in long COVID [27]

For detailed vascular dysfunction and microclot formation mechanisms, see Section 5

8.5.3 Blood-Brain Barrier Energetics (Section 3)

• Energy-Dependent Barrier Function: The blood-brain barrier expresses multiple ATP-binding cassette transporters that are ATP-driven efflux pumps for xenobiotics and endogenous metabolites. These energy-intensive transport systems, along with carrier-mediated transport and receptor-mediated transport, require substantial cellular energy to maintain selective barrier function [92]
• Mitochondrial-BBB Interface in Long COVID: Brain endothelial cells demonstrate high metabolic activity and energy demands for maintaining tight junction integrity and active transport processes. The specific pattern of mitochondrial dysfunction observed in Long COVID patients—including reduced oxidative phosphorylation capacity, impaired creatine-phosphocreatine energy buffering, and exercise-induced succinate dehydrogenase decline—compromises the ATP supply required for these energy-dependent barrier functions, allowing inflammatory mediators and toxic metabolites to access brain tissue [86, 89, 92]

For detailed blood-brain barrier disruption mechanisms, see Section 3

8.5.4 Brain-Muscle Energy Axis Dysfunction

• Systemic Energy Metabolism Failure: Comprehensive metabolomic analysis reveals fundamental energy metabolism dysfunction extending beyond peripheral tissues. The combination of reduced creatine concentrations, impaired TCA cycle function, and S-adenosylmethionine depletion creates systemic energy crisis directly impacting brain function through shared metabolic pathways [86]
• Post-Exertional Cognitive Correlation: The temporal relationship between exercise-induced mitochondrial enzyme decline and worsening cognitive symptoms provides direct mechanistic evidence linking peripheral metabolic dysfunction to neurological manifestations. This brain-muscle energy axis dysfunction explains why physical exertion consistently triggers cognitive symptoms in Long COVID patients [86]

8.6 Long-term Cerebral Hypometabolism

● Persistent FDG-PET Abnormalities: FDG-PET studies demonstrate persistent brain hypometabolism in limbic areas, brainstem, and cerebellum, with 46% of initially hypometabolic voxels remaining hypometabolic at 16 months follow-up, indicating durable metabolic deficits contributing to persistent cognitive symptoms and brain fog [26]

GO TO TOP OF PAGE

9: AUTONOMIC NERVOUS SYSTEM DYSFUNCTION

9.1 Direct Viral Effects on Autonomic Pathways

9.1.1 SARS-CoV-2 Neuroinvasion of Autonomic Centers

• Vagus Nerve Infection: Histopathological analysis provides definitive evidence of SARS-CoV-2 RNA in vagus nerve tissue accompanied by inflammatory cell infiltration. RNA sequencing analysis reveals strong inflammatory responses in neurons, endothelial cells, and Schwann cells correlating with viral load [31]
• Neurotropic Entry Mechanisms: Neuropilin-1 (NRP1) facilitates viral neuronal entry independently of ACE2. Infectious virus recovery from peripheral nerve tissues in postmortem studies provides direct evidence of viral persistence in neural pathways [32]
• Pre-Viremic Neuroinvasion: SARS-CoV-2 RNA was detected in peripheral nervous system and central nervous system tissues at 18 hours post-infection while no viral RNA was detected in blood, indicating direct neuronal invasion rather than hematogenous spread [32]

9.1.2 Viral Persistence in Peripheral Autonomic Neurons

• Peripheral Nerve Viral Reservoirs: SARS-CoV-2 rapidly infects peripheral sensory and autonomic neurons, contributing to central nervous system neuroinvasion before viremia. This establishes viral reservoirs in autonomic pathways that can maintain ongoing dysfunction [32]
• Superior Cervical Ganglion Pathology: Nearly all SCG neurons from hACE2 mice (≈97%) were SARS-N-positive, showing substantial pathology with vacuolated neurons and loss of ganglionic architecture. Infectious virus was not detected in SCGs, indicating abortive infection likely mediated by cytotoxicity [32]

9.2 Autoimmune-Mediated Autonomic Dysfunction

9.2.1 G-Protein Coupled Receptor Autoantibodies

• Universal Autoantibody Targeting: All 31 investigated long COVID patients had between 2-7 different functional autoantibodies targeting G-protein coupled receptors. The most frequently observed autoantibodies were β2-adrenoceptor (β2-fAAB) and muscarinic M2 receptor (M2-fAAB) autoantibodies, present in nearly all patients [33]
• Mechanistic Validation: Immunoadsorption achieving 77% reduction (CI: 58-95%) in β2-adrenergic receptor autoantibodies resulted in 70% of patients being categorized as treatment responders with mean functional improvement of 17.75 points maintained through six months. Patients showed lasting improvements in fatigue, autonomic symptoms, pain, and cognitive function, confirming direct autoantibody-mediated pathogenesis [34]
• Autoimmune Pathway Mechanisms: Post-COVID autonomic dysfunction involves multiple converging pathways including autoantibody formation through molecular mimicry, bystander activation, epitope spreading, and B lymphocyte immortalization. These mechanisms result from dysregulated immune responses where viral antigens share structural similarities with autonomic receptor proteins, leading to cross-reactive antibody production [36]

9.2.2 Autoantibody-Mediated Autonomic Dysfunction

• Systemic Autoantibody Dysregulation: A large cohort study of 80 post-COVID patients showed significant alterations in autoantibodies targeting adrenergic (ADRA2A, ADRB1/2) and muscarinic cholinergic (CHRM1–5) receptors. These dysregulations strongly correlated with key long COVID symptoms, including fatigue, vasomotor instability, and secretomotor dysfunction. Importantly, β2-adrenergic receptor and muscarinic receptor autoantibodies emerged as major drivers of symptom severity, with machine learning models identifying ADRB2, ADRA2A, and STAB1 autoantibodies as the most robust classifiers of post-COVID outcomes [35]
• Pathophysiological Framework: Comprehensive analysis demonstrates that post-COVID autonomic dysfunction results from multisystem involvement affecting cardiovascular, renal, pulmonary, digestive, and nervous systems through persistent inflammation and immune activation. Both innate and adaptive immune responses contribute to autoantibody production, with activated CD4+ T cells releasing pro-inflammatory cytokines and promoting antibody secretion by B cells [36]

9.2.3 Neuropilin-1 Mediated Neuronal Entry

• ACE2-Independent Entry Pathway: NRP-1 expression was confirmed in SCG, TG, and LS-DRG neurons by Western blot. Primary cultured LS-DRG neurons pretreated with EG00229, a selective NRP-1 antagonist, showed viral RNA concentrations reduced by 99.8% in hACE2 neurons and 86.7% in WT neurons [32]
• Universal Entry Mechanism: SARS-CoV-2 neuroinvasion occurred in K18-hACE2 mice, wild-type C57BL/6J mice, and golden Syrian hamsters, demonstrating ACE2-independent pathways [32]

9.2.4 Viral Neuroinvasion Routes

• Neuronal Entry Pathways: SARS-CoV-2 can access autonomic centers through multiple routes: (1) transneuronal transport via olfactory, trigeminal, glossopharyngeal, and vagus nerves expressing ACE-2, NRP1, and TMPRSS2 receptors; (2) hematogenous spread through blood-brain barrier compromise or circumventricular organ penetration, with particular vulnerability of hypothalamic paraventricular nucleus and medullary autonomic centers [36]
• Autonomic Center Targeting: Viral invasion can directly affect hypothalamic-pituitary-adrenal axis function and medullary autonomic reflexes, with evidence suggesting both direct neuronal infection and indirect effects through neuroinflammation and astrocyte activation leading to altered autonomic network connectivity [36]

9.3 Small Fiber Neuropathy Pathogenesis

Small fiber neuropathy has been reported frequently in Long COVID and in the COVID vaccine injured   

9.3.1 Autoimmune-Mediated Small Fiber Damage

• Comprehensive Neuropathy Assessment: Analysis of 17 patients with WHO-defined long COVID using standardized neurological evaluations revealed peripheral neuropathy in 59% of patients. Multiple diagnostic modalities were employed including clinical examination, electrodiagnostic testing, skin biopsies for intraepidermal nerve fiber density, and autonomic function testing [93]
• Objective Pathological Evidence: Among patients who underwent skin biopsy evaluation, 63% (10/16) demonstrated confirmed small fiber loss with reduced intraepidermal nerve fiber density. Additionally, 17% (2/12) of electrodiagnostic tests and 50% (4/8) of autonomic function tests showed abnormal results confirming neuropathy [93]
• Early Onset Neuropathic Changes: Small fiber neuropathy manifestations began within 1 month of COVID-19 onset in the majority of affected patients, with one patient developing critical illness axonal neuropathy and another multifocal demyelinating neuropathy, suggesting rapid development of autoimmune-mediated pathological processes targeting peripheral nerve structures [93]
• Quantitative Neuronal Infection: Immunostaining detected nucleocapsid in ≈41% of TG neurons of hACE2 mice and ≈37% of TG neurons of WT mice. ≈42% of LS-DRG neurons of hACE2 mice and ≈24% of WT neurons were infected. Infectious virus was recovered from TGs and LS-DRGs [32]

9.3.2 Inflammatory Infiltration of Autonomic Fibers

• Heart Rate Variability Dysregulation: In a study of 39 participants (27 with Long COVID and 12 controls), nociception level (NOL) index measurements, reflecting heart rate variability (HRV), indicate dysautonomia in Long COVID patients. The NOL index, a multiparameter tool combining heart rate, HRV(0.15–0.4 Hz band), photoplethysmography amplitude, and skin conductance, shows significant dissociation over time in Long COVID patients with fatigue compared to controls (p = 0.046). This reflects sympathetic/parasympathetic imbalance contributing to autonomic dysfunction [94]
• Fatigue-Associated Autonomic Dysfunction: Long COVID patients with fatigue (n=12) exhibit more pronounced autonomic dysregulation than those without fatigue (n=15), as evidenced by disrupted NOL index patterns during standardized positional testing (lying for 5 minutes, standing for 5 minutes, flexion/extension for 30 seconds, sitting for 2 minutes). Higher NOL index scores in the fatigue group correlate with increased symptom severity, including elevated Nijmegen questionnaire scores (median 36 vs. 20, p=0.002) and PCL-5 scores (31 vs. 18, p=0.001), underscoring the link between autonomic dysregulation and fatigue in Long COVID [94]
• Corneal Autonomic Nerve Degeneration: In a cross-sectional study of 40 patients recovered from COVID-19 (mean 3.7 ± 1.5 months post-diagnosis) and 30 healthy controls, corneal confocal microscopy reveals reduced corneal nerve fiber density (CNFD), corneal nerve branch density (CNBD), and corneal nerve fiber length (CNFL), with increased dendritic cell (DC) density, particularly in patients with neurological symptoms. Patients with neurological symptoms at 4 weeks show lower CNFD (mean difference -4.85 fibers/mm², p=0.032), CNBD (-14.62 branches/mm², p=0.020), and CNFL (-3.35 mm/mm², p=0.012) compared to controls; these changes persist in those with symptoms at 12 weeks (CNFD: -6.94, p=0.008; CNBD: -16.40, p=0.031; CNFL: -4.51, p=0.004). Total DC density is higher in COVID-19 patients (median 39.5 vs. 12.7 cells/mm², p=0.001), indicating immune activation and small fiber damage underlying autonomic dysfunction [95]

9.3.3 Functional Sensory Consequences

• Allodynia Development: Using the von Frey assay, a significant decrease in the amount of pressure required to elicit a withdrawal reflex was noted. 55% of hamsters demonstrated allodynia by 18 hours post-infection, and all remaining hamsters by 3 days post-infection [32]

9.4 Cholinergic System Disruption

9.4.1 Nicotinic Acetylcholine Receptor Dysfunction

• Direct Receptor Interference: In vitro electrophysiological studies in Xenopus oocytes demonstrate that the SARS-CoV-2 spike protein's receptor-binding domain (Spike-RBD, 1 µg/mL) significantly reduces current amplitude in human α4β2 (n=7) and α4α6β2 (n=5) nicotinic acetylcholine receptors (nAChRs), with reductions exceeding 20% at saturating acetylcholine concentrations. The S1 and S2 subunits similarly inhibit α4β2 nAChR activity, likely via an allosteric binding site. No significant effects are observed on α3β4 (n=5) or α7 (n=8) nAChRs, and effects on α3α5β4 (n=4) are equivocal. This selective inhibition of α4-containing nAChRs may disrupt cholinergic neurotransmission, contributing to autonomic dysfunction in Long COVID [96]
• Receptor Availability Disruption: In a case report, (-)-[18F]Flubatine PET imaging demonstrated reduced availability of α4β2 nAChRs in a long COVID patient, which increased significantly after low-dose transdermal nicotine treatment. In vitro electrophysiology studies confirm spike protein interaction with α4β2 and α4α6β2 nAChR subtypes [97]

9.4.2 Impaired Cholinergic Function in Dysautonomia and Small Fiber Neuropathy

• Cholinergic Pathway Targeting: In a cross-sectional study involving 87 post-COVID condition patients, 50 ME/CFS patients, and 50 healthy controls, dysautonomia was identified through inappropriate tachycardia, with postural orthostatic tachycardia syndrome (POTS) diagnosed in 13.8% of post-COVID and 31% of ME/CFS patients. Autonomic testing revealed reduced parasympathetic activation, evidenced by lower expiration/inspiration (E/I) ratio, deep breathing index, and high-frequency respiratory rate interval (HF-RRI) in both patient groups compared to controls, correlating with worsened cognitive performance. Small fiber neuropathy assessments showed pathological sudomotor function (via Sudoscan) in 19.5% of post-COVID and 34% of ME/CFS patients in the palms, and prolonged latencies to heat stimuli (indicating unmyelinated fiber damage), suggesting impaired cholinergic neurotransmission underlying autonomic dysfunction [98]

9.4.3 Impaired Vagal Anti-Inflammatory Pathways

• Parasympathetic Anti-Inflammatory Disruption: SARS-CoV-2 spike protein has a sequence similar to neurotoxins capable of binding to nicotinic acetylcholine receptors (nAChRs), which may disrupt the cholinergic anti-inflammatory pathway and contribute to cholinergic dysfunction in COVID-19 [99]
• Vagal Dysfunction Pathogenesis: In a pilot cross-sectional study of 30 participants with post-COVID-19 condition (PCC) exhibiting vagus nerve-related symptoms, neck ultrasound revealed vagus nerve thickening and hyperechogenicity in 20% of cases, with a mean cross-sectional area of 2.4 ± 0.97 mm² compared to 2 ± 0.52 mm² in COVID-19-recovered controls and 1.9 ± 0.73 mm² in uninfected controls (p=0.080). These structural changes, suggestive of neural inflammation, were associated with functional impairments including dysphonia (78%), dysphagia (75%), reduced esophageal-gastric-intestinal peristalsis (34%), gastroesophageal reflux (34%), hiatal hernia (25%), flattened hemidiaphragms (47%), and reduced maximum inspiratory pressure (62%), indicating compromised parasympathetic function and additional phrenic nerve involvement contributing to autonomic dysfunction in PCC [100]

9.5 Integration with Other Pathogenic Mechanisms

9.5.1 Viral Persistence Interface (Section 1)

• Ongoing Antigen-Driven Dysfunction: SARS-CoV-2 spike protein persistence in neural tissues provides continuous pathogenic stimulus for autonomic dysfunction. Viral reservoir maintenance in autonomic pathways creates sustained autoantigen presentation [32]

9.5.2 Immune Dysregulation Amplification (Section 2)

• Autoimmune-Autonomic Coupling: G-protein coupled receptor autoantibodies create direct mechanistic links between systemic immune dysregulation and autonomic dysfunction. Autoantibody levels correlate with symptom severity, indicating immune system targeting of autonomic receptors [33]

9.5.3 Neuroinflammatory Network Effects (Section 4)

• Central-Peripheral Inflammatory Loops: Vagus nerve inflammation and central autonomic network dysfunction create bidirectional pathogenic amplification. Peripheral autonomic dysfunction perpetuates central neuroinflammation through disrupted anti-inflammatory signaling [31]
• Persistent Cytokine Dysregulation: IL-6, TNF-α, IL-1β, IL-17, and CCL2 remain pathologically elevated up to 8 months post-infection. Cerebrospinal fluid studies show pathogenic IL-6 elevation correlating with autonomic dysfunction severity [101]
• Satellite Glial Cell Infection: SARS-S was present throughout hACE2 LS-DRGs, and also in satellite glial cells (SGCs). Infected SGCs were observed with many appearing to be activated, noted by the presence of extended cellular processes [32]

9.5.4 Self-Perpetuating Pathogenic Mechanisms

• Autoantibody-Inflammation Cycles: Pathogenic cycles where autoantibodies perpetuate inflammation and inflammation sustains autoantibody production create chronic autonomic dysfunction [101]

9.5.5 Multi-Modal Pathogenic Convergence

• Systemic Integration: Post-COVID autonomic dysfunction represents convergence of multiple pathogenic mechanisms including persistent inflammation-hypoxia-sympathetic overactivation cycles, renin-angiotensin system imbalance, and direct viral effects on autonomic pathways. This multi-modal pathogenesis explains the complex and variable presentation of autonomic symptoms in long COVID patients [36]

9.56 Sleep disorders 

Sleep disturbances are common in Long COVID, affecting a significant portion of patients, with issues like insomnia, excessive daytime sleepiness, and poor sleep quality being frequently reported and potentially worsening over time post-infection

Because sleep and immunity are bidirectionally linked, sleepiness or sleep disturbance side effects reported after some of the COVID-19 vaccines advise an academic research line in the context of physiological or pathological neuroimmune interactions.  IL-1β, INF-γ and TNF-α pro-inflammatory cytokines inhibit orexinergic neurons promoting sleepiness after peripheral activation of the innate immune system induced by the novel COVID-19 vaccines  (Garrido-Suarez B 2022)

Studies suggest a link between alpha-synuclein aggregation, sleep disturbances, and long COVID, indicating a potential role for the protein in long-term neurological symptoms.  : A skin biopsy test recently detected a form of aggregated alpha-synuclein in many patients with idiopathic RBD, a condition that can be a precursor to Parkinson's and other neurodegenerative diseases. (CS Shreiber 2025) (Chang M 2024) 

Chang M et al SARS-CoV-2 Spike Protein 1 Causes Aggregation of α-Synuclein via Microglia-Induced Inflammation and Production of Mitochondrial ROS: Potential Therapeutic Applications of Metformin Biomedicines 2024 

9.57 Overlap with EDS and Hypermobility disorder  

Hypermobility spectrum disorders (HSD) and hypermobile Ehlers–Danlos syndrome (hEDS) are the most common joint hypermobility conditions encountered by physicians, with hypermobile and classical EDS accounting for >90% of all cases. Hypermobility has been detected in up to 30–57% of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), fibromyalgia, postural orthostatic tachycardia syndrome (POTS), and long COVID (LC) compared to the general population. Extrapulmonary symptoms, including musculoskeletal pain, dysautonomia disorders, cognitive disorders, and fatigue, are seen in both LC and HSD. Additionally, ME/CFS has overlapping symptoms with those seen in HSD. Mast cell activation and degranulation occurring in both LC and ME/CFS may result in hyperinflammation and damage to connective tissue in these patients, thereby inducing hypermobility. Persistent inflammation may result in the development or worsening of HSD. Hence, screening for hypermobility and other related conditions including fibromyalgia, POTS, ME/CFS, chronic pain conditions, joint pain, and myalgia is essential for individuals experiencing LC (Ganish R 2024)

GO TO TOP OF PAGE

• 10: Spike protein and risk of Neurodegenerative Disease  

  Numerous studies now show a risk of neurodegenerative disease after recovering from even a mild infection.  

  A study published in the journal Nature Medicine (Duff E 2025)  investigated whether both mild and severe cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are linked to changes in brain biomarkers associated with Alzheimer’s disease.  By analyzing blood samples from the United Kingdom (U.K.) Biobank participants, the researchers found that individuals who had COVID-19 showed signs of increased brain pathology   The Aβ42:Aβ40 ratio, a key marker of beta-amyloid buildup, was lower in COVID-19-positive participants compared to their matched controls. A reduced ratio of these proteins is commonly linked to Alzheimer’s pathology.  And, elevated markers of tau and nFL were noted 

  
  

  Spike 1 protein either from the virus or from the vaccines, can induce amyloid-β aggregation, which may be associated with the neurological symptoms experienced in COVID-19.  

  SARS COV 2 is the only coronavirus with prion-like domains on the spike protein. (Kyriakopoulos et al., 2022, Perez et al., 2023,  Tetz G 2021, Seneff et al., 2023). 

  Spike protein been shown to bind to amyloidogenic proteins such as amyloid-beta (Aβ), alpha-synuclein (α-syn), tau, prion and TDP-43, accelerating their aggregation and misfolding and leading to neurodegeneration (Cao et al., 2023, Idrees and Kumar, 2021, Nyström and Hammarström, 2022, Trougakos et al., 2022). 

  In the presence of S1, there is also a reduced clearance of Aβ1–42 (Hsu et al., 2021). These aspects suggest that SP tends to act as a functional amyloid and form toxic aggregates (Tavassoly et al., 2020).  S1 also shows a “glycine zipper” motif, which is associated with susceptibility to misfolding and thus prion formation (Parry et al., 2023).  Spike protein can also induce the expression of prion protein (PrP) in the brain via hyperinflammation (Parry et al., 2023). The increase in prion glycoproteins (PrPC) can lead to misfolding of the prion conformation and generate prions and prion-related diseases (Norrby, 2011). In addition, SP activates signalling pathways such as mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK), which are involved in neurotoxicity and prion-like disease processes (Kyriakopoulos et al., 2022, Suzuki et al., 2021). And it affects the transmembrane glycoprotein CD147, which can also promote neurodegenerative processes (Cosentino and Marino, 2022).

  t SP is involved in the increased expression of α-Syn, a protein that tends to aggregate (Wu et al., 2022), which is thought to be responsible for a number of neurodegenerative diseases (Brás et al., 2020). In addition, the inhibitory effect of SP on the α7-nAChR of the cholinergic system has been demonstrated (Changeux et al., 2020; O´Brien et al., 2023; Parry et al., 2023; Tillman et al., 2023). In the human nervous system (HNS), α7-nAChRs are highly expressed, especially in the hippocampus, cortex and limbic regions, and are involved in cognition, sensory information processing, attention, working memory and reward pathways (Parry et al., 2023). The inhibitory interaction of SP with CNS α7-nAChRs can also be considered pro-neurodegenerative, as the important role of α7-nAChRs in the pathogenesis of Alzheimer's disease (reduction of α7-nAChRs in the brain, especially in the hippocampus) has long been known (Ma and Qian, 2019, Parri et al., 2011). (Paso A 2022) 

  *Galectin-9 (Gal-9)is elevated in Long COVID (see Section 7 above)  It isone of the most abundant beta-galactosidase-binding proteins secreted by active microglia, is elevated in brain tissue and cerebrospinal fluid in patients with AD, associating with cognitive impairments. Gal-9 binds to toll-like receptor 4 (TLR4) on microglia and activates the NLR family, pyrin domain containing 3 (NLRP3) inflammasome, promoting the secretion of interleukin-1β (IL-1β) and IL-18, which are toxic to neurons. (Guo X)
  In a study by Hillard P et al they found that  SARS-CoV-2 spike protein accelerates Alzheimer’s Disease-Related Dementia through increased cerebrovascular inflammation and deterioration of BBB in hACE2 Mice. The AT1R blocker Losartan attenuated the detrimental effect of the spike protein by reducing cerebrovascular inflammation and improving cerebral blood flow 

  * A peer-reviewed study by Sanguigno L et al  found that the SARS-CoV-2 spike S1 protein can directly induce neuronal death via a defined epigenetic and necroptotic pathway.

  
  

  Sanguigno L et al Role of NRP1/HDAC4/CREB/RIPK1 Axis in SARS-CoV2 S1 Spike Subunit-Induced Neuronal Toxicity SAFEB Bioadvances May 2025 

  
  

  Muscle damage 

  Muscle abnormalities worsen after post-exertional malaise in long COVID | Nature Communications
  https://www.nature.com/articles/s41467-023-44432-3

  The findings in this paper include: 

  a.  amyloid myopathy (In the presence of S1, there is also a reduced clearance of Aβ1–42. . These aspects suggest that SP tends to act as a functional amyloid and form toxic aggregates.    Spike protein has prion properties and this leads to more prion formation.   (amyloid, tau, alpha synuclein, etc) 

  b.   mitochondrial damage and lower intrinsic mitochondrial function  ( Studies show that the spike protein can impair mitochondrial function and bioenergetics.)

  c.   lower oxidative phosphorylation capacity which translates to reduced ATP production  

  d.   a reduction in glycolytic metabolites and accumulation of fatigue inducing metabolites  

  e.  vascular: capillary networks to skeletal muscle may be impaired leading to local hypoxia  / spike protein damages the endothelial lining 

  f.   autoantibodies, particularly those targeting G-protein-coupled receptors, may play a role in post-exertional malaise (PEM)   / some have suggested that spike protein shares molecular mimicry with mitochondria 

  The microclots are morphologically changing with exercise with a shift of large microclots fragmenting into more numerous smaller ones !!  

  In the old precovid days,  exercise was recommended to help clear blood clots 

  But with Long COVID and PVS ,  exercise does not help clear the microclots and in those with PEM ,  exercise is making the problem worse, potentially impairing  oxygen transport and/or utilization which will  lower exercise tolerance / capacity and even potentially damages muscle fibers. 

  AND all of this leads to persistent microvascular dysfunction and endothelial damage.  

  In this study,  they showed that there could be an up to 72 hour delay in this sci-fi microclot fragmentation with even submaximal exercise.  

  Callum T et al   Exercise-induced Changes in Microclotting and Cytokine Levels Point to Vascular Injury and Inflammation in People with Long COVID Science for ME 2025

INTEGRATED SELF-PERPETUATING PATHOGENIC NETWORK

10.1 Mechanistic Integration

"The integrated pathogenic network presented represents a synthesis of findings from multiple independent studies with varying methodologies, patient populations, and time points post-infection. While individual mechanisms are well-supported by cited research, the proposed interconnections between pathogenic mechanisms represent a theoretical framework based on available evidence. Further research is needed to validate the specific mechanistic relationships and temporal sequences described in this integrated model. Clinical manifestations and underlying mechanisms may vary significantly between individual patients and populations."

• Viral Persistence → Immune Dysregulation → Neuroinflammation: SARS-CoV-2 spike protein persistence in brain pericytes and CD16+ monocytes up to 15 months post-infection provides ongoing antigenic stimulation that drives G-protein coupled receptor autoantibody formation, present in all investigated long COVID patients, which subsequently maintains chronic microglial activation and neuroinflammatory responses [3, 5, 33]
• BBB Disruption → Vascular → White Matter Integration: BBB hyperpermeability extending up to 7 months post-infection enables thrombotic endothelialitis with microclot formation, creating conditions that facilitate neuroinflammatory infiltration and contribute to CCL11-mediated white matter damage through disrupted oligodendrocyte function [10, 37, 65]
• Metabolic → Immune → Autonomic Coupling: Mitochondrial dysfunction with impaired ATP synthesis compromises energy-dependent immune regulation while galectin-9 elevation (97% diagnostic sensitivity) correlates with multiple inflammatory markers, creating metabolic-immune dysfunction that perpetuates autonomic nervous system dysregulation [24, 26, 86]

10.2 Self-Perpetuating Network Maintenance

• Chronic Immune Activation Cycles: Persistent neuroinflammation involves chronic activation of circulating T and B lymphocytes by cross-reacting viral epitopes that target brain microglia, while complement dysregulation with terminal complex imbalance maintains thromboinflammatory signatures at 6+ months post-infection [39, 78]
• Systemic Inflammatory State Maintenance: Cross-pathogen immune activation involving T cell and myeloid activation with pro-inflammatory cytokine production creates an ongoing inflammatory state with transcriptional signatures similar to those observed in recovered COVID-19 patients, maintaining network dysfunction beyond viral clearance [38]
• Structural and Functional Remodeling: Sustained endothelial dysfunction leads to permanent structural changes maintaining chronic hypoperfusion, while ongoing neuroinflammation impairs neuroplastic responses required for recovery, creating irreversible modifications that perpetuate dysfunction [19, 26]

10.3 Clinical Integration Framework

• Multi-Modal Pathogenic Convergence: Post-COVID autonomic dysfunction represents convergence of multiple pathogenic mechanisms including persistent inflammation-hypoxia-sympathetic overactivation cycles, renin-angiotensin system imbalance, and direct viral effects on autonomic pathways, explaining the complex and variable presentation of neurological symptoms [36]
• Network-Level Biomarker Patterns: Integrated dysfunction manifests as correlated elevation of galectin-9, complement components, neurofilament markers, and vascular dysfunction indicators, demonstrating that long COVID neurological manifestations result from network-level rather than single-system pathology [24, 47, 78]

● Temporal Network Evolution: Transition from acute viral effects to chronic network dysfunction occurs through failed immune resolution mechanisms, with T cell exhaustion and persistent inflammatory mediator elevation at 8+ months representing established self-perpetuating pathogenic networks [42, 62]

•  

  
  

   

  GO TO TOP OF PAGE

   

   

   

GENETIC SUSCEPTIBILITY FACTORS

11.1 FOXP4 Gene Variants

• Risk Polymorphism: FOXP4 polymorphisms are associated with increased expression and may contribute to long COVID susceptibility [11]
• Neurological Development Role: FOXP4 is critical for CNS development and maturation, with mutations associated with neurodevelopmental disorders [11]

11.2 Additional Genetic Factors

• NR1H2 Gene: Genetic variants in NR1H2 have been associated with neurological complications in long COVID. The gene is also implicated in cognitive impairments observed in Alzheimer's disease, suggesting a potential link through shared neuroinflammatory pathways [11]
• SLC6A20 Gene: This gene encodes an amino acid transporter that may facilitate SARS-CoV-2 cellular entry. Certain genetic variants have been associated with altered susceptibility to COVID-19 and may influence neurological outcomes, although direct causality remains to be established [11]

REFERENCES

[1] Santos Guedes de Sa K, Silva J, Bayarri-Olmos R, Brinda R, Alec Rath Constable R, Colom Diaz PA, Kwon DI, Rodrigues G, Wenxue L, Baker C, Bhattacharjee B, Wood J, Tabacof L, Liu Y, Putrino D, Horvath TL, Iwasaki A. A causal link between autoantibodies and neurological symptoms in long COVID. medRxiv [Preprint]. 2024 Jun 19:2024.06.18.24309100. doi: 10.1101/2024.06.18.24309100. PMID: 38947091; PMCID: PMC11213106.

[2] Antar AAR, Yu T, Demko ZO, Hu C, Tornheim JA, Blair PW, Thomas DL, Manabe YC. Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. Front Immunol. 2023 Apr 28;14:1147549. doi: 10.3389/fimmu.2023.1147549. PMID: 37187756; PMCID: PMC10176965.

[3] Rong Z, Mai H, Ebert G, Kapoor S, Puelles VG, Czogalla J, Hu S, Su J, Prtvar D, Singh I, Schädler J, Delbridge C, Steinke H, Frenzel H, Schmidt K, Braun C, Bruch G, Ruf V, Ali M, Sühs KW, Nemati M, Hopfner F, Ulukaya S, Jeridi D, Mistretta D, Caliskan ÖS, Wettengel JM, Cherif F, Kolabas ZI, Molbay M, Horvath I, Zhao S, Krahmer N, Yildirim AÖ, Ussar S, Herms J, Huber TB, Tahirovic S, Schwarzmaier SM, Plesnila N, Höglinger G, Ondruschka B, Bechmann I, Protzer U, Elsner M, Bhatia HS, Hellal F, Ertürk A. Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19. Cell Host Microbe. 2024 Dec 11;32(12):2112-2130.e10. doi: 10.1016/j.chom.2024.11.007. Epub 2024 Nov 29. PMID: 39615487.

[4] Peluso MJ, Swank ZN, Goldberg SA, Lu S, Dalhuisen T, Borberg E, Senussi Y, Luna MA, Chang Song C, Clark A, Zamora A, Lew M, Viswanathan B, Huang B, Anglin K, Hoh R, Hsue PY, Durstenfeld MS, Spinelli MA, Glidden DV, Henrich TJ, Kelly JD, Deeks SG, Walt DR, Martin JN. Plasma-based antigen persistence in the post-acute phase of COVID-19. Lancet Infect Dis. 2024 Jun;24(6):e345-e347. doi: 10.1016/S1473-3099(24)00211-1. Epub 2024 Apr 8. PMID: 38604216; PMCID: PMC11650779.

[5] Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, Hall E, Herrera M, Parikh P, Guevara-Coto J, Triche TJ, Scott P, Hekmati S, Maglinte D, Chang X, Mora-Rodríguez RA, Mora J. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. Front Immunol. 2022 Jan 10;12:746021. doi: 10.3389/fimmu.2021.746021. PMID: 35082777; PMCID: PMC8784688.

[6] Chen B, Julg B, Mohandas S, Bradfute SB; RECOVER Mechanistic Pathways Task Force. Viral persistence, reactivation, and mechanisms of long COVID. Elife. 2023 May 4;12:e86015. doi: 10.7554/eLife.86015. PMID: 37140960; PMCID: PMC10159620.

[7] Vojdani A, Vojdani E, Saidara E, Maes M. Persistent SARS-CoV-2 Infection, EBV, HHV-6 and Other Factors May Contribute to Inflammation and Autoimmunity in Long COVID. Viruses. 2023 Jan 31;15(2):400. doi: 10.3390/v15020400. PMID: 36851614; PMCID: PMC9967513.

[8] Seibert FS, Stervbo U, Wiemers L, Skrzypczyk S, Hogeweg M, Bertram S, Kurek J, Anft M, Westhoff TH, Babel N. Severity of neurological Long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors. Autoimmun Rev. 2023 Nov;22(11):103445. doi: 10.1016/j.autrev.2023.103445. Epub 2023 Sep 7. PMID: 37689093.

[9] Lee MH, Perl DP, Steiner J, Pasternack N, Li W, Maric D, Safavi F, Horkayne-Szakaly I, Jones R, Stram MN, Moncur JT, Hefti M, Folkerth RD, Nath A. Neurovascular injury with complement activation and inflammation in COVID-19. Brain. 2022 Jul 29;145(7):2555-2568. doi: 10.1093/brain/awac151. PMID: 35788639; PMCID: PMC9278212.

[10] Greene C, Connolly R, Brennan D, Laffan A, O'Keeffe E, Zaporojan L, O'Callaghan J, Thomson B, Connolly E, Argue R, Meaney JFM, Martin-Loeches I, Long A, Cheallaigh CN, Conlon N, Doherty CP, Campbell M. Blood-brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat Neurosci. 2024 Mar;27(3):421-432. doi: 10.1038/s41593-024-01576-9. Epub 2024 Feb 22. Erratum in: Nat Neurosci. 2024 May;27(5):1019. doi: 10.1038/s41593-024-01644-0. PMID: 38388736; PMCID: PMC10917679.

[11] Talkington GM, Kolluru P, Gressett TE, Ismael S, Meenakshi U, Acquarone M, Solch-Ottaiano RJ, White A, Ouvrier B, Paré K, Parker N, Watters A, Siddeeque N, Sullivan B, Ganguli N, Calero-Hernandez V, Hall G, Longo M, Bix GJ. Neurological sequelae of long COVID: a comprehensive review of diagnostic imaging, underlying mechanisms, and potential therapeutics. Front Neurol. 2025 Feb 7;15:1465787. doi: 10.3389/fneur.2024.1465787. PMID: 40046430; PMCID: PMC11881597.

[12] Jeong GU, Lyu J, Kim KD, Chung YC, Yoon GY, Lee S, Hwang I, Shin WH, Ko J, Lee JY, Kwon YC. SARS-CoV-2 Infection of Microglia Elicits Proinflammatory Activation and Apoptotic Cell Death. Microbiol Spectr. 2022 Jun 29;10(3):e0109122. doi: 10.1128/spectrum.01091-22. Epub 2022 May 5. PMID: 35510852; PMCID: PMC9241873.

[13] Theoharides TC, Kempuraj D. Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID. Cells. 2023 Feb 22;12(5):688. doi: 10.3390/cells12050688. PMID: 36899824; PMCID: PMC10001285.

[14] Albornoz EA, Amarilla AA, Modhiran N, Parker S, Li XX, Wijesundara DK, Aguado J, Zamora AP, McMillan CLD, Liang B, Peng NYG, Sng JDJ, Saima FT, Fung JN, Lee JD, Paramitha D, Parry R, Avumegah MS, Isaacs A, Lo MW, Miranda-Chacon Z, Bradshaw D, Salinas-Rebolledo C, Rajapakse NW, Wolvetang EJ, Munro TP, Rojas-Fernandez A, Young PR, Stacey KJ, Khromykh AA, Chappell KJ, Watterson D, Woodruff TM. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Mol Psychiatry. 2023 Jul;28(7):2878-2893. doi: 10.1038/s41380-022-01831-0. Epub 2022 Nov 1. PMID: 36316366; PMCID: PMC10615762.

[15] Cama VF, Marín-Prida J, Acosta-Rivero N, Acosta EF, Díaz LO, Casadesús AV, Fernández-Marrero B, Gilva-Rodríguez N, Cremata-García D, Cervantes-Llanos M, Piniella-Matamoros B, Sánchez D, Del Rosario-Cruz L, Borrajero I, Díaz A, González Y, Pentón-Arias E, Montero-González T, Guillen-Nieto G, Pentón-Rol G. The microglial NLRP3 inflammasome is involved in human SARS-CoV-2 cerebral pathogenicity: A report of three post-mortem cases. J Neuroimmunol. 2021 Dec 15;361:577728. doi: 10.1016/j.jneuroim.2021.577728. Epub 2021 Sep 29. PMID: 34619427; PMCID: PMC8480138.

[16] Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133-146. doi: 10.1038/s41579-022-00846-2. Epub 2023 Jan 13. Erratum in: Nat Rev Microbiol. 2023 Jun;21(6):408. doi: 10.1038/s41579-023-00896-0. PMID: 36639608; PMCID: PMC9839201.

[17] Menezes F, Palmeira JDF, Oliveira JDS, Argañaraz GA, Soares CRJ, Nóbrega OT, Ribeiro BM, Argañaraz ER. Unraveling the SARS-CoV-2 spike protein long-term effect on neuro-PASC. Front Cell Neurosci. 2024 Dec 18;18:1481963. doi: 10.3389/fncel.2024.1481963. PMID: 39744674; PMCID: PMC11688492.

[18] Klein R, Soung A, Sissoko C, Nordvig A, Canoll P, Mariani M, Jiang X, Bricker T, Goldman J, Rosoklija G, Arango V, Underwood M, Mann JJ, Boon A, Dowrk A, Boldrini M. COVID-19 induces neuroinflammation and loss of hippocampal neurogenesis. Res Sq [Preprint]. 2021 Oct 29:rs.3.rs-1031824. doi: 10.21203/rs.3.rs-1031824/v1. Update in: Brain. 2022 Dec 19;145(12):4193-4201. doi: 10.1093/brain/awac270. PMID: 34729556; PMCID: PMC8562542.

[19] Kruger A, Joffe D, Lloyd-Jones G, Khan MA, Šalamon Š, Laubscher GJ, Putrino D, Kell DB, Pretorius E. Vascular Pathogenesis in Acute and Long COVID: Current Insights and Therapeutic Outlook. Semin Thromb Hemost. 2025 Apr;51(3):256-271. doi: 10.1055/s-0044-1790603. Epub 2024 Sep 30. PMID: 39348850; PMCID: PMC11906225.

[20] Huang S, Zhou Z, Yang D, Zhao W, Zeng M, Xie X, Du Y, Jiang Y, Zhou X, Yang W, Guo H, Sun H, Liu P, Liu J, Luo H, Liu J. Persistent white matter changes in recovered COVID-19 patients at the 1-year follow-up. Brain. 2022 Jun 3;145(5):1830-1838. doi: 10.1093/brain/awab435. PMID: 34918020; PMCID: PMC8754808.

[21] Huang S, Zhou X, Zhao W, Du Y, Yang D, Huang Y, Chen Y, Zhang H, Yang G, Liu J, Luo H. Dynamic white matter changes in recovered COVID-19 patients: a two-year follow-up study. Theranostics. 2023 Jan 1;13(2):724-735. doi: 10.7150/thno.79902. PMID: 36632218; PMCID: PMC9830428.

[22] Hosp JA, Reisert M, Dressing A, Götz V, Kellner E, Mast H, Arndt S, Waller CF, Wagner D, Rieg S, Urbach H, Weiller C, Schröter N, Rau A. Cerebral microstructural alterations in Post-COVID-condition are related to cognitive impairment, olfactory dysfunction and fatigue. Nat Commun. 2024 May 18;15(1):4256. doi: 10.1038/s41467-024-48651-0. PMID: 38762609; PMCID: PMC11102465.

[23] Kesler SR, Franco-Rocha OY, De La Torre Schutz A, Lewis KA, Aziz RM, Henneghan AM, Melamed E, Brode WM. Altered functional brain connectivity, efficiency, and information flow associated with brain fog after mild to moderate COVID-19 infection. Sci Rep. 2024 Sep 27;14(1):22094. doi: 10.1038/s41598-024-73311-0. PMID: 39333726; PMCID: PMC11437042.

[24] Elahi S, Rezaeifar M, Osman M, Shahbaz S. Exploring the role of galectin-9 and artemin as biomarkers in long COVID with chronic fatigue syndrome: links to inflammation and cognitive function. Front Immunol. 2024 Sep 25;15:1443363. doi: 10.3389/fimmu.2024.1443363. PMID: 39386210; PMCID: PMC11461188.

[25] Szögi T, Borsos BN, Masic D, Radics B, Bella Z, Bánfi A, Ördög N, Zsiros C, Kiricsi Á, Pankotai-Bodó G, Kovács Á, Paróczai D, Botkáné AL, Kajtár B, Sükösd F, Lehoczki A, Polgár T, Letoha A, Pankotai T, Tiszlavicz L. Novel biomarkers of mitochondrial dysfunction in Long COVID patients. Geroscience. 2025 Apr;47(2):2245-2261. doi: 10.1007/s11357-024-01398-4. Epub 2024 Nov 4. PMID: 39495479; PMCID: PMC11979091.

[26] Horowitz RI, Freeman PR, Bruzzese J. Persistent brain metabolic impairment in long COVID patients with persistent clinical symptoms: a nine-month follow-up [18F]FDG-PET study. Eur J Nucl Med Mol Imaging. 2024 Jul;51(8):2395-2408. doi: 10.1007/s00259-024-06731-9. PMID: 38862619; PMCID: PMC11153273.

[27] Noonong K, Chatatikun M, Surinkaew S, Kotepui M, Hossain R, Bunluepuech K, Noothong C, Tedasen A, Klangbud WK, Imai M, Kawakami F, Kubo M, Kitagawa Y, Ichikawa H, Kanekura T, Sukati S, Somsak V, Udomwech L, Ichikawa T, Nissapatorn V, Tangpong J, Indo HP, Majima HJ. Mitochondrial oxidative stress, mitochondrial ROS storms in long COVID pathogenesis. Front Immunol. 2023 Dec 22;14:1275001. doi: 10.3389/fimmu.2023.1275001. PMID: 38187378; PMCID: PMC10766822.

[28] Molnar T, Lehoczki A, Fekete M, Varnai R, Zavori L, Erdo-Bonyar S, Simon D, Berki T, Csecsei P, Ezer E. Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches. Geroscience. 2024 Oct;46(5):5267-5286. doi: 10.1007/s11357-024-01165-5. Epub 2024 Apr 26. PMID: 38668888; PMCID: PMC11336094.

[29] Vollbracht C, Kraft K. Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C. Front Pharmacol. 2022 Apr 29;13:899198. doi: 10.3389/fphar.2022.899198. PMID: 35571085; PMCID: PMC9100929.

[30] Parthasarathy U, Martinelli R, Vollmann EH, Best K, Therien AG. The impact of DAMP-mediated inflammation in severe COVID-19 and related disorders. Biochem Pharmacol. 2022 Jan;195:114847. doi: 10.1016/j.bcp.2021.114847. Epub 2021 Nov 18. PMID: 34801526; PMCID: PMC8600760.

[31] Woo MS, Shafiq M, Fitzek A, Dottermusch M, Altmeppen H, Mohammadi B, Mayer C, Bal S, Hoffmann A, Rissiek B, Binder M, Glatzel M, Schulte-Schrepping J, Schultze JL, Heppner FL, Friese MA, Magnus T. Vagus nerve inflammation contributes to dysautonomia in COVID-19. Acta Neuropathol. 2023 Sep;146(3):387-394. doi: 10.1007/s00401-023-02612-x. PMID: 37552271; PMCID: PMC10412500.

[32] Fenrich M, Mrdenovic S, Balog M, Tomic S, Zjalic M, Roncevic A, Djekic D, Vujanovic L, Zdravkovic N, Bankovic V, Jovanovic I, Bufan B, Milenkovic M, Arsenijevic A, Milosevic V, Jovanovic M, Milovanovic J, Arsenijevic N, Lukic ML. SARS-CoV-2 Rapidly Infects Peripheral Sensory and Autonomic Neurons, Contributing to Central Nervous System Neuroinvasion before Viremia. Int J Mol Sci. 2024 Jul 30;25(15):8245. doi: 10.3390/ijms25158245. PMID: 39125825; PMCID: PMC11311705.

[33] Wallukat G, Hohberger B, Wenzel K, Fürst J, Schulze-Rothe S, Wallukat A, Hönicke AS, Müller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100. PMID: 33997024; PMCID: PMC8093903.

[34] Stein E, Heindrich C, Wittke K, Kedor C, Rust R, Freitag H, Sotzny F, Krüger A, Tölle M, Grabowski P, Scheibenbogen C, Kim L. Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study. Lancet Reg Health Eur. 2024 Dec 12;49:101161. doi: 10.1016/j.lanepe.2024.101161. PMID: 39759581; PMCID: PMC11699797.

[35] Sotzny F, Filgueiras IS, Kedor C, Freitag H, Wittke K, Bauer S, Sepúlveda N, Mathias da Fonseca DL, Baiocchi GC, Marques AHC, Kim M, Lange T, Plaça DR, Luebber F, Paulus FM, De Vito R, Jurisica I, Schulze-Forster K, Paul F, Bellmann-Strobl J, Rust R, Hoppmann U, Shoenfeld Y, Riemekasten G, Heidecke H, Cabral-Marques O, Scheibenbogen C. Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front Immunol. 2022 Sep 27;13:981532. doi: 10.3389/fimmu.2022.981532. PMID: 36238301; PMCID: PMC9552223.

[36] Jammoul M, Naddour J, Madi A, Reslan MA, Hatoum F, Zeineddine J, Abou-Kheir W, Lawand N. Investigating the possible mechanisms of autonomic dysfunction post-COVID-19. Auton Neurosci. 2023 Mar;245:103071. doi: 10.1016/j.autneu.2022.103071. Epub 2022 Dec 24. PMID: 36580747; PMCID: PMC9789535.

[37] Turner S, Khan MA, Putrino D, Woodcock A, Kell DB, Pretorius E. Long COVID: pathophysiological factors and abnormalities of coagulation. Trends Endocrinol Metab. 2023 Jun;34(6):321-344. doi: 10.1016/j.tem.2023.03.002. Epub 2023 Apr 19. PMID: 37080828; PMCID: PMC10113134.

[38] Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, Fehlmann T, Stein JA, Schaum N, Lee DP, Calcuttawala K, Vest RT, Berdnik D, Lu N, Hahn O, Gate D, McNerney MW, Channappa D, Cobos I, Ludwig N, Schulz-Schaeffer WJ, Keller A, Wyss-Coray T. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021 Jul;595(7868):565-571. doi: 10.1038/s41586-021-03710-0. Epub 2021 Jun 21. Erratum in: Nature. 2021 Oct;598(7882):E4. doi: 10.1038/s41586-021-04080-3. PMID: 34153974; PMCID: PMC8400927.

[39] Stefano GB, Büttiker P, Weissenberger S, Martin A, Ptacek R, Kream RM. Editorial: The Pathogenesis of Long-Term Neuropsychiatric COVID-19 and the Role of Microglia, Mitochondria, and Persistent Neuroinflammation: A Hypothesis. Med Sci Monit. 2021 May 10;27:e933015. doi: 10.12659/MSM.933015. PMID: 34016942; PMCID: PMC8120907.

[40] Zuo W, He D, Liang C, Du S, Hua Z, Nie Q, Zhou X, Yang M, Tan H, Xu J, Yu Y, Zhan Y, Zhang Y, Gu X, Zhu W, Zhang H, Li H, Sun W, Sun M, Liu X, Liu L, Cao C, Li R, Li J, Zhang Y, Zhang Y, Guo J, Zhao L, Zhang CP, Liu H, Wang S, Xiao F, Wang Y, Wang Z, Li H, Cao B. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect Dis. 2024 Aug;24(8):845-855. doi: 10.1016/S1473-3099(24)00171-3. Epub 2024 Apr 22. PMID: 38663423.

[41] Goh D, Lim JCT, Fernaíndez SB, Joseph CR, Edwards SG, Neo ZW, Lee JN, Caballero SG, Lau MC, Yeong JPS. Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID. Front Immunol. 2022 Sep 5;13:939989. doi: 10.3389/fimmu.2022.939989. Erratum in: Front Immunol. 2022 Oct 06;13:1036894. doi: 10.3389/fimmu.2022.1036894. PMID: 36131932; PMCID: PMC9483160.

[42] Yin K, Peluso MJ, Luo X, Thomas R, Shin MG, Neidleman J, Andrew A, Young KC, Ma T, Hoh R, Anglin K, Huang B, Argueta U, Lopez M, Valdivieso D, Asare K, Deveau TM, Munter SE, Ibrahim R, Ständker L, Lu S, Goldberg SA, Lee SA, Lynch KL, Kelly JD, Martin JN, Münch J, Deeks SG, Henrich TJ, Roan NR. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat Immunol. 2024 Feb;25(2):218-225. doi: 10.1038/s41590-023-01724-6. Epub 2024 Jan 11. PMID: 38212464; PMCID: PMC10834368.

[43] Visvabharathy L, Hanson BA, Orban ZS, Lim PH, Palacio NM, Jimenez M, Clark JR, Graham EL, Liotta EM, Tachas G, Penaloza-MacMaster P, Koralnik IJ. T cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVID. medRxiv [Preprint]. 2022 Oct 21:2021.08.08.21261763. doi: 10.1101/2021.08.08.21261763. PMID: 34401886; PMCID: PMC8366804.

[44] Heming M, Li X, Räuber S, Mausberg AK, Börsch AL, Hartlehnert M, Singhal A, Lu IN, Fleischer M, Szepanowski F, Witzke O, Brenner T, Dittmer U, Yosef N, Kleinschnitz C, Wiendl H, Stettner M, Meyer Zu Hörste G. Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity. 2021 Jan 12;54(1):164-175.e6. doi: 10.1016/j.immuni.2020.12.011. Epub 2020 Dec 23. PMID: 33382973; PMCID: PMC7831653.

[45] Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, Juno JA, Burrell LM, Kent SJ, Dore GJ, Kelleher AD, Matthews GV. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022 Feb;23(2):210-216. doi: 10.1038/s41590-021-01113-x. Epub 2022 Jan 13. PMID: 35027728.

[46] Wiech M, Chroscicki P, Swatler J, Stepnik D, De Biasi S, Hampel M, Brewinska-Olchowik M, Maliszewska A, Sklinda K, Durlik M, Wierzba W, Cossarizza A, Piwocka K. Remodeling of T Cell Dynamics During Long COVID Is Dependent on Severity of SARS-CoV-2 Infection. Front Immunol. 2022 Jun 10;13:886431. doi: 10.3389/fimmu.2022.886431. PMID: 35757700; PMCID: PMC9226563.

[47] Liew F, Efstathiou C, Fontanella S, Richardson M, Saunders R, Swieboda D, Sidhu JK, Ascough S, Moore SC, Mohamed N, Nunag J, King C, Leavy OC, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M, Harris VC, Houchen-Wolloff L, Greening NJ, Lone NI, Thorpe M, Thompson AAR, Rowland-Jones SL, Docherty AB, Chalmers JD, Ho LP, Horsley A, Raman B, Poinasamy K, Marks M, Kon OM, Howard LS, Wootton DG, Quint JK, de Silva TI, Ho A, Chiu C, Harrison EM, Greenhalf W, Baillie JK, Semple MG, Turtle L, Evans RA, Wain LV, Brightling C, Thwaites RS, Openshaw PJM; PHOSP-COVID collaborative group; ISARIC investigators. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nat Immunol. 2024 Apr;25(4):607-621. doi: 10.1038/s41590-024-01778-0. Epub 2024 Apr 8. PMID: 38589621; PMCID: PMC11003868.

[48] Negro-Demontel L, Maleki AF, Reich DS, Kemper C. The complement system in neurodegenerative and inflammatory diseases of the central nervous system. Front Neurol. 2024 Jul 3;15:1396520. doi: 10.3389/fneur.2024.1396520. PMID: 39022733; PMCID: PMC11252048.

[49] Bernal KDE, Whitehurst CB. Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients. Virus Res. 2023 Sep;334:199157. doi: 10.1016/j.virusres.2023.199157. Epub 2023 Jun 26. PMID: 37364815; PMCID: PMC10292739.

[50] Kanwal A, Zhang Z. Exploring common pathogenic association between Epstein Barr virus infection and long-COVID by integrating RNA-Seq and molecular dynamics simulations. Front Immunol. 2024 Sep 26;15:1435170. doi: 10.3389/fimmu.2024.1435170. PMID: 39391317; PMCID: PMC11464307.

[51] Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, Liu J, Harville TO. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS One. 2021 Sep 3;16(9):e0257016. doi: 10.1371/journal.pone.0257016. Erratum in: PLoS One. 2024 Nov 20;19(11):e0314426. doi: 10.1371/journal.pone.0314426. PMID: 34478478; PMCID: PMC8415618.

[52] Adiguzel Y, Bogdanos DP, Shoenfeld Y. Molecular/antigenic mimicry and immunological cross-reactivity explains SARS-CoV-2-induced autoimmunity. Autoimmun Rev. 2025 Jun 24;24(7):103811. doi: 10.1016/j.autrev.2025.103811. Epub 2025 Apr 8. PMID: 40209971.

[53] Tarasco MC, Iacomino N, Mantegazza R, Cavalcante P. COVID-19, Epstein-Barr virus reactivation and autoimmunity: Casual or causal liaisons? J Microbiol Immunol Infect. 2025 Mar 27:S1684-1182(25)00076-3. doi: 10.1016/j.jmii.2025.03.014. Epub ahead of print. PMID: 40175252.

[54] Jernbom AF, Skoglund L, Pin E, Sjöberg R, Tegel H, Hober S, Rostami E, Rasmusson A, Cunningham JL, Havervall S, Thålin C, Månberg A, Nilsson P. Prevalent and persistent new-onset autoantibodies in mild to severe COVID-19. Nat Commun. 2024 Oct 17;15(1):8941. doi: 10.1038/s41467-024-53356-5. PMID: 39414823; PMCID: PMC11484904.

[55] Verma D, Church TM, Swaminathan S. Epstein-Barr Virus Lytic Replication Induces ACE2 Expression and Enhances SARS-CoV-2 Pseudotyped Virus Entry in Epithelial Cells. J Virol. 2021 Jun 10;95(13):e0019221. doi: 10.1128/JVI.00192-21. Epub 2021 Jun 10. PMID: 33853968; PMCID: PMC8316011.

[56] Bonetto V, Pasetto L, Lisi I, Carbonara M, Zangari R, Ferrari E, Punzi V, Luotti S, Bottino N, Biagianti B, Moglia C, Fuda G, Gualtierotti R, Blasi F, Canetta C, Montano N, Tettamanti M, Camera G, Grimoldi M, Negro G, Rifino N, Calvo A, Brambilla P, Biroli F, Bandera A, Nobili A, Stocchetti N, Sessa M, Zanier ER. Markers of blood-brain barrier disruption increase early and persistently in COVID-19 patients with neurological manifestations. Front Immunol. 2022 Dec 15;13:1070379. doi: 10.3389/fimmu.2022.1070379. PMID: 36591311; PMCID: PMC9798841.

[57] Zhang L, Zhou L, Bao L, Liu J, Zhu H, Lv Q, Liu R, Chen W, Tong W, Wei Q, Xu Y, Deng W, Gao H, Xue J, Song Z, Yu P, Han Y, Zhang Y, Sun X, Yu X, Qin C. SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther. 2021 Sep 6;6(1):337. doi: 10.1038/s41392-021-00719-9. PMID: 34489403; PMCID: PMC8419672.

[58] Taquet M, Skorniewska Z, Hampshire A, Chalmers JD, Ho LP, Horsley A, Marks M, Poinasamy K, Raman B, Leavy OC, Richardson M, Elneima O, McAuley HJC, Shikotra A, Singapuri A, Sereno M, Saunders RM, Harris VC, Houchen-Wolloff L, Greening NJ, Mansoori P, Harrison EM, Docherty AB, Lone NI, Quint J, Sattar N, Brightling CE, Wain LV, Evans RE, Geddes JR, Harrison PJ; PHOSP-COVID Study Collaborative Group. Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization. Nat Med. 2023 Oct;29(10):2498-2508. doi: 10.1038/s41591-023-02525-y. Epub 2023 Aug 31. PMID: 37653345; PMCID: PMC10579097.

[59] Kempuraj D, Aenlle KK, Cohen J, Mathew A, Isler D, Pangeni RP, Nathanson L, Theoharides TC, Klimas NG. COVID-19 and Long COVID: Disruption of the Neurovascular Unit, Blood-Brain Barrier, and Tight Junctions. Neuroscientist. 2024 Aug;30(4):421-439. doi: 10.1177/10738584231194927. Epub 2023 Sep 11. PMID: 37694571.

[60] Braga J, Lepra M, Kish SJ, Rusjan PM, Nasser Z, Verhoeff N, Vasdev N, Bagby M, Boileau I, Husain MI, Kolla N, Garcia A, Chao T, Mizrahi R, Faiz K, Vieira EL, Meyer JH. Neuroinflammation After COVID-19 With Persistent Depressive and Cognitive Symptoms. JAMA Psychiatry. 2023 Aug 1;80(8):787-795. doi: 10.1001/jamapsychiatry.2023.1321. PMID: 37256580; PMCID: PMC10233457.

[61] VanElzakker MB, Bues HF, Brusaferri L, Kim M, Saadi D, Ratai EM, Dougherty DD, Loggia ML. Neuroinflammation in post-acute sequelae of COVID-19 (PASC) as assessed by [11C]PBR28 PET correlates with vascular disease measures. Brain Behav Immun. 2024 Jul;119:713-723. doi: 10.1016/j.bbi.2024.04.015. Epub 2024 Apr 18. PMID: 38642615; PMCID: PMC11225883.

[62] Schultheiß C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes SS, Bosurgi L, Dutzmann J, Sedding D, Frese T, Girndt M, Höll JI, Gekle M, Mikolajczyk R, Binder M. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022 Jun 21;3(6):100663. doi: 10.1016/j.xcrm.2022.100663. PMID: 35732153; PMCID: PMC9214726.

[63] Plantone D, Hone L, Righy C, De Angelis MV, Foschi M, Salemi G, Eichau S, Alonso A, Brodziak A, Bayas A, Onofrj M. Neurofilament light chain and glial fibrillary acid protein levels are elevated in post-mild COVID-19 or asymptomatic SARS-CoV-2 cases. Sci Rep. 2024 Mar 16;14(1):6206. doi: 10.1038/s41598-024-57093-z. PMID: 38493206; PMCID: PMC10944451.

[64] Almulla AF, Al-Hakeim HK, Abed MS, Carvalho AF, Maes M. The tryptophan catabolite or kynurenine pathway in long COVID disease: A systematic review and meta-analysis. Neuroscience. 2024 Dec 20;563:50-61. doi: 10.1016/j.neuroscience.2024.11.005. PMID: 39510296.

[65] Fernández-Castañeda A, Lu P, Geraghty AC, Song E, Lee MH, Wood J, O'Dea MR, Dutton S, Shamardani K, Nwangwu K, Mancusi R, Yalçın B, Taylor KR, Mercier GA, Chiang JJ, Villeda SA, Whetstone WD, Liddelow SA, Vogel H, Monje M. Mild respiratory COVID-19 causes multi-lineage neural cell and myelin loss. Cell. 2022 May 12;185(10):1800-1815.e16. doi: 10.1016/j.cell.2022.04.025. PMID: 35513073; PMCID: PMC9037454.

[66] Chagas LDS, Serfaty CA. The Influence of Microglia on Neuroplasticity and Long-Term Cognitive Sequelae in Long COVID: Impacts on Brain Development and Beyond. Int J Mol Sci. 2024 Mar 29;25(7):3819. doi: 10.3390/ijms25073819. PMID: 38612629; PMCID: PMC11011312.

[67] Fontes-Dantas FL, Fernandes GG, Gutman EG, De Lima EV, Antonio LS, Hammerle MB, Mota-Araujo HP, Colodeti LC, Araújo SMB, Froz GM, da Silva TN, Duarte LA, Salvio AL, Pires KL, Leon LAA, Vasconcelos CCF, Romão L, Savio LEB, Silva JL, da Costa R, Clarke JR, Da Poian AT, Alves-Leon SV, Passos GF, Figueiredo CP. SARS-CoV-2 Spike protein induces TLR4-mediated long-term cognitive dysfunction recapitulating post-COVID-19 syndrome in mice. Cell Rep. 2023 Mar 28;42(3):112189. doi: 10.1016/j.celrep.2023.112189. Epub 2023 Feb 17. PMID: 36857178; PMCID: PMC9935273.

[68] Yang AC, Kern F, Losada PM, Agam MR, Maat CA, Schmartz GP, Fehlmann T, Stein JA, Schaum N, Lee DP, Calcuttawala K, Vest RT, Berdnik D, Lu N, Hahn O, Gate D, McNerney MW, Channappa D, Cobos I, Ludwig N, Schulz-Schaeffer WJ, Keller A, Wyss-Coray T. Dysregulation of brain and choroid plexus cell types in severe COVID-19. Nature. 2021 Jul;595(7868):565-571. doi: 10.1038/s41586-021-03710-0. Epub 2021 Jun 21. Erratum in: Nature. 2021 Oct;598(7882):E4. doi: 10.1038/s41586-021-04080-3. PMID: 34153974; PMCID: PMC8400927.

[69] Mavrikaki M, Lee JD, Solomon IH, Slack FJ. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity. 2021 Jun 8;54(6):1304-1314.e6. doi: 10.1016/j.immuni.2021.05.002. PMID: 34043940; PMCID: PMC8110638.

[70] Low RN, Low RJ, Akrami A. A review of cytokine-based pathophysiology of Long COVID symptoms. Front Med (Lausanne). 2023 Mar 31;10:1011936. doi: 10.3389/fmed.2023.1011936. PMID: 37064029; PMCID: PMC10103649.

[71] Pommy JM, Cohen A, Mahil A, Glass Umfleet L, Swanson SJ, Franczak M, Obarski S, Ristow K, Wang Y. Changes in cerebrovascular reactivity within functional networks in older adults with long-COVID. Front Neurol. 2025 Mar 26;16:1504573. doi: 10.3389/fneur.2025.1504573. PMID: 40206293; PMCID: PMC11981175.

[72] Ajčević M, Iscra K, Furlanis G, Stella AB, Cillotto T, Mearelli F, Bussani R, Gigli GL, Valente M, Manganotti P. Cerebral hypoperfusion in post-COVID-19 cognitively impaired subjects revealed by arterial spin labeling MRI. Sci Rep. 2023 Mar 16;13(1):4322. doi: 10.1038/s41598-023-30886-8. PMID: 36928388; PMCID: PMC10020588.

[73] Montezano AC, Millar RC, Rios FJ, Stead S, Patel S, Vedanayagam P, Sullivan J, Dikalov SI, Harrison DG, Touyz RM. SARS-CoV-2 spike protein induces endothelial inflammation via ACE2 independently of viral replication. Sci Rep. 2023 Sep 7;13(1):14705. doi: 10.1038/s41598-023-41115-3. PMID: 37679440; PMCID: PMC10484922.

[74] Ryu JK, Sozmen EG, Dixit K, Pochareddy S, Schenk AL, Petersen MA, Uzgil B, Bedi SS, Akassoglou K. Fibrin drives thromboinflammation and neuropathology in COVID-19. Nature. 2024 Oct;634(8032):905-913. doi: 10.1038/s41586-024-07873-4. PMID: 39232163; PMCID: PMC11457707.

[75] Kruger A, Vlok M, Turner S, Venter C, Laubscher GJ, Kell DB, Pretorius E. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022 Sep 17;21(1):190. doi: 10.1186/s12933-022-01623-4. PMID: 36131342; PMCID: PMC9491257.

[76] Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, Kell DB. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021 Aug 5;20(1):172. doi: 10.1186/s12933-021-01359-7. PMID: 34353327; PMCID: PMC8342055.

[77] Althaus K, Marini I, Zlamal J, Pelzl L, Singh A, Häberle H, Mehrländer M, Hammer S, Schulze H, Bode C, Staudacher I, Wesche J, Leinøe E, Søgaard OS, Borst O, Gawaz M, Bakchoul T. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood. 2021 Mar 4;137(9):1061-1071. doi: 10.1182/blood.2020008762. PMID: 33170938; PMCID: PMC7938417.

[78] Cervia-Hasler C, Brüningk SC, Hoch T, Fan B, Muzio G, Thompson RC, Ceglarek L, Meledin R, Westermann P, Emmenegger M, Taeschler P, Zurbuchen Y, Pons M, Menges D, Ballouz T, Cervia C, Luu AM, Adamo S, Brugger SD, Mairpady Shambat S, Huber LC, Nilsson J, Held U, Puhan MA, Hess C, Beerenwinkel N, Claassen M, Kouyos RD, Fröhlich-Nowoisky J, Pöschl U, Bollen Y, Boyman O; Zurich SARS-CoV-2 Cohort. Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science. 2024 Feb 23;383(6685):eadg7942. doi: 10.1126/science.adg7942. PMID: 38359836.

[79] Walker M, Venter C, Laubscher GJ, Federico E, Pretorius E. Abstract WP326: Microclots, Erythrocytes, and the Coagulation Cascade in Long COVID. Stroke. 2024;55(Suppl_1):WP326. doi: 10.1161/str.55.suppl_1.WP326.

[80] Yuan M, Lu R, Liu Y, Zhu H, Wang H, Wang J, Song Y, Yang L, Xiao M. White matter changes in recovered COVID-19 patients: insights from DTI, DKI, and NODDI metrics. Front Neurol. 2025 Jul 18;16:1580262. doi: 10.3389/fneur.2025.1580262. PMID: 39022755; PMCID: PMC11256789.

[81] Boito G, Ceccaldi P, Le Coz M, Corouge I, Girard OM, Cocozza S, Palombo M, Barillot C, Gozzi N. MRI with generalized diffusion encoding reveals damaged white matter in patients previously hospitalized for COVID-19 and with persisting symptoms at follow-up. Brain Commun. 2023 Nov 10;5(6):fcad284. doi: 10.1093/braincomms/fcad284. PMID: 38024081; PMCID: PMC10667767.

[82] Fernández-Castañeda A, Lu P, Geraghty AC, Song E, Lee MH, Wood J, O'Dea MR, Dutton S, Shamardani K, Nwangwu K, Mancusi R, Yalçın B, Taylor KR, Mercier GA, Chiang JJ, Villeda SA, Whetstone WD, Liddelow SA, Vogel H, Monje M. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell. 2022 May 12;185(10):1800-1815.e16. doi: 10.1016/j.cell.2022.04.025. PMID: 35513073; PMCID: PMC9037454.

[83] Plantone D, Hone L, Righy C, De Angelis MV, Foschi M, Salemi G, Eichau S, Alonso A, Brodziak A, Bayas A, Onofrj M. Neurofilament light chain and glial fibrillary acid protein levels are elevated in post-mild COVID-19 or asymptomatic SARS-CoV-2 cases. Sci Rep. 2024 Mar 16;14(1):6206. doi: 10.1038/s41598-024-57093-z. PMID: 38493206; PMCID: PMC10944451.

[84] Almulla AF, Thipakorn Y, Zhou B, Vojdani A, Paunova R, Maes M. The tryptophan catabolite or kynurenine pathway in long COVID disease: A systematic review and meta-analysis. Neuroscience. 2024 Dec 17;563:268-277. doi: 10.1016/j.neuroscience.2024.10.021. PMID: 39424264.

[85] Schapira AH, Falabella M, Priori G, Bisiacchi P, Ferini-Strambi L, Zoccolella S, Doshi P. Mitochondrial function is impaired in long COVID patients. Ann Med. 2025;57(1):2528167. doi: 10.1080/07853890.2025.2528167. PMID: 39655688.

[86] Appelman B, Charlton BT, Goulding RP, Kerkhoff TJ, Breedveld EA, Noort W, Offringa C, Posthuma JJ, Schutgens REG, Bloemers FW, van Weeghel M, Schomakers BV, Coelho P, Posthuma JJ, van Vugt M, Wiersinga WJ, van de Beek D, Bogaards JA, van der Poll T, de Brabander J, van der Hoeven JG, Vlaar APJ, Koopmans M, Haagmans BL, van Gorp ECM. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nat Commun. 2024 Jan 9;15(1):17. doi: 10.1038/s41467-023-44432-3. PMID: 38191524; PMCID: PMC10774284.

[87] Finnigan LEM, Cassar MP, Jafarpour M, Sultana A, Ashkir Z, Azer K, Neubauer S, Tyler DJ, Raman B, Valkovič L. 1H and 31P MR Spectroscopy to Assess Muscle Mitochondrial Dysfunction in Long COVID. Radiology. 2024 Dec;313(3):e233173. doi: 10.1148/radiol.233173. PMID: 39718498.

[88] Godlewska BR, Saunders KEA, Bilderbeck AC, Rendell JM, Khalifeh H, Sharpe M, Cowen PJ, Harrison PJ. Brain and muscle chemistry in myalgic encephalitis/chronic fatigue syndrome (ME/CFS) and long COVID: a 7T magnetic resonance spectroscopy study. Mol Psychiatry. 2025 Jan;30(1):1-12. doi: 10.1038/s41380-025-03108-8. PMID: 39737813.

[89] Huth TK, Alzghari SK, Palanivel R, Kim YJ, Barbeau WA, Hutton JE, Fragala MS. Reduced tissue creatine levels in patients with long COVID-19: A cross-sectional study. JCSM Clin Rep. 2023 Jul 28;8(4):103-111. doi: 10.1002/crt2.67. PMID: 37575416; PMCID: PMC10394531.

[90] Martínez-Gómez LE, Ibáñez-Shimabukuro M, López-Alcalde S, Andrés-León E, Ciria-Abad S, Buzón MJ, Muñoz-Hernández R, Carrillo J, Blanco J, Martinez-Picado J, Benito JM, González García J, Moreno S, Rallón NI, Restrepo C. Reinforcing the Evidence of Mitochondrial Dysfunction in Long COVID Patients Using a Multiplatform Mass Spectrometry-Based Metabolomics Approach. J Proteome Res. 2024 May 3;23(5):1738-1751. doi: 10.1021/acs.jproteome.4c00142. PMID: 38566450; PMCID: PMC11062327.

[91] Maes M, Vasupanrajit A, Jirakran K, Klomkliew P, Chanchaem P, Tunvirachaisakul C, Payungporn S. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol Psychiatry. 2023 Feb;28(2):564-578. doi: 10.1038/s41380-022-01836-9. PMID: 36385527; PMCID: PMC9666327.

[92] Zhao Z, Nelson AR, Betsholtz C, Zlokovic BV. Establishment and Dysfunction of the Blood-Brain Barrier. Cell. 2015 Nov 19;163(5):1064-1078. doi: 10.1016/j.cell.2015.10.067. PMID: 26590417; PMCID: PMC4655822.

[93] Oaklander AL, Mills AJ, Kelley M, Toran LS, Smith B, Dalakas MC, Nath A. Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID. Neurol Neuroimmunol Neuroinflamm. 2022 Mar 1;9(3):e1146. doi: 10.1212/NXI.0000000000001146. PMID: 35232750; PMCID: PMC8889896.

[94] Barizien N, Le Guen M, Russel S, Touche P, Huang F, Vallée A. Clinical characterization of dysautonomia in long COVID-19 patients. Sci Rep. 2021 Jul 7;11(1):14042. doi: 10.1038/s41598-021-93546-5. PMID: 34234251; PMCID: PMC8263555.

[95] Bitirgen G, Korkmaz C, Zamani A, Ozkagnici A, Zengin N, Ponirakis G, Malik RA. Corneal confocal microscopy identifies corneal nerve fibre loss and increased dendritic cells in patients with long COVID. Br J Ophthalmol. 2022 Sep;106(9):1312-1317. doi: 10.1136/bjophthalmol-2021-319450. PMID: 34312122.

[96] Skok M, Grailhe R, Changeux JP. The SARS-CoV-2 Virus and the Cholinergic System: Spike Protein Interaction with Human Nicotinic Acetylcholine Receptors and the Nicotinic Agonist Varenicline. Biomolecules. 2023 Mar 20;13(3):566. doi: 10.3390/biom13030566. PMID: 36979500; PMCID: PMC10046893.101]

[97] Steinberg A, Starkman JS, Robello RC, Stein SM, Turcios NL, Demmer RT, Al-Delaimy WK. Long COVID -- a critical disruption of cholinergic neurotransmission? Bioelectron Med. 2025 Jan 14;12(1):1. doi: 10.1186/s42234-025-00167-8. PMID: 40011942; PMCID: PMC11742009.

[98] Azcue N, Del Pino R, Acera M, Fernández-Valle T, Ayo-Mentxakatorre N, Pérez-Concha T, Murueta-Goyena A, Lafuente JV, Prada A, López de Munain A, Ruiz Irastorza G, Martín-Iglesias D, Ribacoba L, Gabilondo I, Gómez-Esteban JC, Tijero-Merino B. Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome. J Transl Med. 2023 Nov 15;21(1):814. doi: 10.1186/s12967-023-04678-3. PMID: 37968647; PMCID: PMC10648633.

[99] Wessels I, Rink L, Lippold N, Staudt V. Cholinergic dysfunction in COVID-19: frantic search and hoping for the best. Naunyn Schmiedebergs Arch Pharmacol. 2023 Apr;396(4):669-684. doi: 10.1007/s00210-022-02346-9. PMID: 36527471; PMCID: PMC9735034.

[100] Polito M, Piserà M, Sangregorio G, De Santis R, Bortolotti P, Gianturco L, Trojan D, Bechi G, Rasciti L, Mariotto S, Bozzetti S, Ferrari S, Girelli D, Tacconelli E, Cattelan A. Vagus nerve dysfunction in the post-COVID-19 condition: a pilot cross-sectional study. Clin Microbiol Infect. 2024 Feb;30(2):258.e9-258.e15. doi: 10.1016/j.cmi.2023.11.013. PMID: 38070777.

[101] Russell AE, Sneyd R, Halpin S, Levy A, Sechi A, Plumb T, Richter AG, Pearce F, De Soyza A, Marks M, Wain L, Brightling C, Scott JT; PHOSP-COVID Collaborative Group. Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs. Open Forum Infect Dis. 2024 May 16;11(6):ofae279. doi: 10.1093/ofid/ofae279. PMID: 38854517; PMCID: PMC11138192.

{102} Mangonotti P et al Mapping brain changes in post-COVID-19 cognitive decline via FDG PET hypometabolism and EEG slowing Nature 2025 https://www.nature.com/articles/s41598-025-04815-6 

{103} Halma M et al Breaking the silence: Recognizing post-vaccination syndrome Helyon 2025 , https://doi.org/10.1093/arclin/acaf064

{104}  Y. Zhao et al SARS-CoV-2, long COVID, prion disease and neurodegeneration Front. Neurosci., 16 (2022 Sep 27)

{105] C.V. O'Brien, L. Weber, K. Hueffer, M.M. Weltzin SARS-CoV-2 spike ectodomain targets α7 nicotinic acetylcholine receptors J. Biol. Chem., 299 (5) May 2025 May 22

{106} Menezes P et al Unraveling the SARS-CoV-2 spike protein long-term effect on neuro-PASC Front Cell Neurosci. 2024 Dec 18;18:1481963. doi: 10.3389/fncel.2024.1481963 

{107} Ding Q et al  Long-term effects of SARS-CoV-2 infection on human brain and memory. Cell Death Discov. 2023  9:196. doi: 10.1038/s41420-023-01512-z [DOI] [PMC free article] [PubMed] [Google Scholar]

{108} Solomon I. H., et al. (2020). Neuropathological features of COVID-19. N. Engl. J. Med. 383, 989–992. doi: 10.1056/NEJMc2019373

{109}  Fernandez-Castaneda A. et al. (2022). Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell 185, 2452–2468. doi: 10.1016/j.cell.2022.06.008

{110}  Elboraay T et al Long-term neurological and cognitive impact of COVID-19: a systematic review and meta-analysis in over 4 million patients BMC Neurology June 2025 

{111} Poso P  Spike protein-related proteinopathies: A focus on the neurological side of spikeopathies Annals of Anatomy June 2025 

{112} Stein J SARS-CoV-2 infection and persistence in the human body and brain at autopsy Nature 2021   

{113} Tetz G et al Prion-like domains in spike protein of SARS-CoV-2 differ across its variants and enable changes in affinity to ACE2 Microorganisms 2021 

{114} Miller S et al SARS-CoV-2 induces Alzheimer's disease-related amyloid-β pathology in ex vivo human retinal explants and retinal organoids Sci Adv 2025  

{115} Cao S et al Spike protein fragments promote Alzheimer's amyloidogenesis ACS Appl. Mater. Interfaces, 15 (2023), pp. 40317-40329

{116} Idres S et al SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration Biochem. Biophys. Res. Commun 2021  

{117}  Nystrom S et al Amyloidogenesis of SARS-CoV-2 spike protein J. Am. Chem. Soc., 144 (2022)

{118} Trougakas T et al Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis Trends Mol. Med., 28 (2022),

{119} Hsu T et al The effects of Aβ(1–42) binding to the SARS-CoV-2 spike protein S1 subunit and angiotensin-converting enzyme 2 Int. J. Mol. Sci., 22 (2021)

{120} Hsu T et al The effects of Aβ(1–42) binding to the SARS-CoV-2 spike protein S1 subunit and angiotensin-converting enzyme 2 Int. J. Mol. Sci., 22 (2021)

{121} Tavassoly Q et al ,Seeding brain protein aggregation by sars-cov-2 as a possible long-term complication of covid-19 infection ACS Chem. Neurosci., 11 (2020)

{122} Kyriakopoulos A et al Mitogen activated protein kinase (mapk) activation, p53, and autophagy inhibition characterize the severe acute respiratory syndrome coronavirus 2 (sars-cov-2) spike protein induced neurotoxicity Cureus, 14 (2022) 

{123} Perez J et al Jakob disease: 26 cases of the human version of mad-cow disease, days after a COVID-19 injection IJVTPR, 3 (1) (2023

{124} Parry P et al Spikeopathy': COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA Biomedicines, 11 (2023) 

{125}  Cosentino M et al Understanding the Pharmacology of COVID-19 mRNA Vaccines: Playing Dice with the Spike? Int. J. Mol. Sci., 23 (2022)

{126} Wu X et al SARS-CoV-2 proteins interact with alpha synuclein and induce lewy body-like pathology in vitro Int. J. Mol. Sci., 23 (2022)

{127} J.P. Changeux, et al. A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications Comptes Rendus Biol., 343 (2020

{128} B.C.V. O’Brien et al. SARS-CoV-2 spike ectodomain targets α7 nicotinic acetylcholine receptorsJ. Biol. Chem., 299 2023

{129} T.S. Tillman et al. SARS-CoV-2 Spike Protein Downregulates Cell Surface alpha7nAChR through a Helical Motif in the Spike Neck ACS Chem. Neurosci 2023 

{130} V. Alves, S.et al.SARS-CoV-2 Spike protein alters microglial purinergic signaling Front. Immunol., 14 (2023)

{131} T.C. Theoharides et al Role of SARS-CoV-2 spike-protein-induced activation of microglia and mast cells in the pathogenesis of neuro-COVID Cells, 12 (5) (2023)

{131}  Guo X et al Galectin-9 activates the TLR4-NLRP3 inflammasome pathway and promotes tau pathology in Alzheimer’s disease Brain Behavior Immunity October 2025 

{132} Almulia A et al Brain-targeted autoimmunity is strongly associated with Long COVID and its chronic fatigue syndrome as well as its affective symptoms J of Advanced Research 2025 

{133} Belluci M et al Post-SARS-CoV-2 infection and post-vaccine-related neurological complications share clinical features and the same positivity to anti-ACE2 antibodies Frontiers in Immunology 2024  

{134} De Sa KS et al. A causal link between autoantibodies and neurological symptoms in long COVID. medRxiv. 2024

{135} Montovani M et al Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study Biomedicines 2024 

{136} Talkington G et al Neurological sequelae of long COVID: a comprehensive review of diagnostic imaging, underlying mechanisms, and potential therapeutics Frontiers of Neuroscience 2025 

{137} Brogna C et al Detection of recombinant Spike protein in the blood of individuals vaccinated against SARS-CoV-2: Possible molecular mechanisms Journal of Proteomics Clinical Applications August 31 2023 

{138} Chen Y et al New-onset autoimmune phenomena post-COVID-19 vaccination  Immunology 2022 

{139} Guedes K et al  A causal link between autoantibodies and neurological symptoms in long BMJ June 2024  

{140} Chen H et al Transfer of IgG from Long COVID patients induces symptomology in mice bioRxiV June 2024 

{141} K Santos Guedes de Sa, et al A causal link between autoantibodies and neurological symptoms in long COVID medRxiV 2024 

{142} Hillard P et al   SARS-CoV-2 Spike Protein Accelerates Alzheimer’s Disease-Related Dementia Through Increased Cerebrovascular Inflammation in hACE2 Mice Stroke Meeting Abstract 2025 

{143} Patterson B et al Detection of S1 spike protein in CD16+ monocytes up to 245 days in SARS-CoV-2-negative post-COVID-19 vaccine syndrome (PCVS) individuals Human Vaccines and Immunotherapeutics 2025 

{144} Schreiber C et al  Intravenous SARS-CoV-2 Spike protein induces neuroinflammation and alpha-Synuclein accumulation in brain regions relevant to Parkinson’s disease Brain Behavior and Immunity 2025  

{145} Kakeya H et al Significant Increase in Excess Deaths after Repeated COVID-19 Vaccination in Japan JMA 2025  

{146} Ota N et al Expression of SARS-CoV-2 spike protein in cerebral Arteries: Implications for hemorrhagic stroke Post-mRNA vaccination J of Clinical Neuroscience 2025 

{147} Rose J. Breakthrough Infection Signal in VAERS Corroborates IgG4-Mediated Increased Susceptibility to SARS-CoV-2. Sci Public Health Policy Law. 2025

{148} Hamzaraj K et al  Impact of Circulating Anti-Spike Protein Antibody Levels on Multi-Organ Long COVID Symptoms Vaccines 2024 

{149} Duff E et al  Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection Nature Medicine 2025 

{150} Leung W et al  COVID-19 Infection and Vaccination and Its Relation to Amyloidosis: What Do We Know Currently? Vaccines 2024 

{151} Garrido-Suarez B et al Reactogenic sleepiness after COVID-19 vaccination. A hypothesis involving orexinergic system linked to inflammatory signals Sleep Medicine 2022) 

{152} Shan D et al Association between COVID-19 infection and new-onset dementia in older adults: a systematic review and meta-analysis BMC Neurology 2024 

{153} Montgomery, S., et al. (2024) SARS-CoV-2 infection and risk of subsequent demyelinating diseases: national register-based cohort study. Brain Communications.

{154} Domínguez-Andrés J, et al. The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses. medRxiv, 2021 

{155} Ganesh R et al Long COVID and hypermobility spectrum disorders have shared pathophysiology Frontiers Neuroscience 2024 

{157} (Garrido-Suarez B 2022)  et al Reactogenic sleepiness after COVID-19 vaccination. A hypothesis involving orexinergic system linked to inflammatory signals Sleep Medicine 2022

{158) Ismail II et al. A systematic review of cases of CNS demyelination following COVID-19 vaccination. J Neuroimmunol. 2022 

{159} Voysey M et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomized controlled trials in Brazil, South Africa, and the UK. Lancet. 2021

{160} Mele A et al A Case of Multiple Sclerosis Uncovered Following Moderna SARS-CoV-2 Vaccination Cureus 2022  

{161} Nakano H et al.  Relapsing Anti-MOG Antibody-associated Disease Following COVID-19 Vaccination: A Rare Case Report and Review of the Literature Internal Medicine Advance Publication 2022 

{161} Khavet-Khoei et al COVID-19 mRNA vaccination leading to CNS inflammation: a case series J Neuro 2021 

{162} Garcia Dominquea et al Autoimmune Encephalitis, Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Analysis of the Vaccine Adverse Event Reporting System (VAERS) Garcia Dominquez M et al medRxiv November 2024  

{163} Hamed V et al. CNS Demyelination Syndromes Following COVID-19 Vaccination: A Case Series J Pharm Bioallied Sci 2024 

{164} Moretti G et al Multiple sclerosis and optic neuritis triggered by COVID-19 mRNA Neuroimmunology Reports 2024 

(165} Elnahry L et al Multiple sclerosis and optic neuritis triggered by COVID-19 mRNA International J of Neuroscience 2022 

{166} Garnert JA et al.   Clinical onset of CNS demyelinating disease after COVID-19 vaccination: denovo disease? Multiple Sclerosis November 2021   

{167} Havla, J et al. First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine J. Neurol. 2022

{168} Jarius, S et al. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature [published online ahead of print, 2022 Jun 23]J. Neurol. 2022

{169} Allugmani M. New Onset Multiple Sclerosis Post-COVID-19 Vaccination and Correlation With Possible Predictors in a Case-Control Study Cureus 2023 

{170} Rinaldi V et al CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic reviewFront. Neurol., 30 November 2022 Multiple Sclerosis and Neuroimmunology 2022

{171} Tagliaferri A et al A rare presentation of undiagnosed multiple sclerosis after the COVID-19 vaccine J of Community Hospital Internal Medicine Perspectives 2021 

{172} Maniscalco, GT et al. Severe multiple sclerosis relapse after COVID-19 vaccination: a case report Front. Neurol. 2021

{173} Mumoli, L et al  ADEM anti-MOG antibody-positive after SARS-CoV2 vaccination Neurol. Sci. 2022

{174} Simone, AM et al Acute disseminated encephalomyelitis associated with anti-myelin oligodendrocyte glycoprotein (MOG-IGG) antibody in a patient with recent vaccination against SARS-CoV-2 J. Neurol. Sci. 2021

{175} Salunke M et al Spectrum of various CNS inflammatory demyelination diseases following COVID-19 vaccinations Acta Neurologica 2024 

{176} Ravindr G et al. Tumefactive Demyelinating Brain Lesion Developing after Administration of Adenovector-Based COVID-19 Vaccine A Case Report Neurology India 2022 

{177} Lee, JS et al. Changes in the incidence of optic neuritis before and after COVID-19: A nationwide study 2017-2022. Ophthalmology. September 13, 2024

{178} Roy, Madhurima et al Optic neuritis following COVID-19 vaccination: Coincidence or side-effect? - A case series Indian Journal of Ophthalmology 2022  

{179} Czarnowsks A et al Case report: First manifestation of multiple sclerosis temporally correlated with COVID-19 vaccination Front. Neurol., 14 February 2023 Sec. Multiple Sclerosis and Neuroimmunology 

{180} Lim E et al. The association between acute transverse myelitis and COVID‐19 vaccination in Korea: Self‐controlled case series study.  Eur J Neurol 2024 

{181} Guarnaccia J et al Transverse myelitis as a first event of multiple sclerosis precipitated by Pfizer-BioNTech COVID-19 vaccination Neuroimmunology Reports 2022 

{182} Do K et al Onset of Guillain-Barre Syndrome and Transverse Myelitis Following COVID-19 Vaccination Cureus 2023 

{183} Satoshi M et al Acute autoimmune transverse myelitis following COVID-19 vaccination A case report Medicine 2021 

{184} Kahn A et al Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature J of Neurology 2022

{185} Serrano del Pueblo V et al Brain and cognitive changes in patients with long COVID compared with infection-recovered control subjects Brain 2024

GO TO TOP OF PAGE